

Review

Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases



Salvador Harguindey^{a,*,1}, Daniel Stanciu^a, Jesús Devesa^b, Khalid Alfarouk^c, Rosa Angela Cardone^d, Julian David Polo Orozco^a, Pablo Devesa^e, Cyril Rauch^f, Gorka Orive^g, Eduardo Anitua^h, Sébastien Roger^{i,j,1}, Stephan J. Reshkin^{d,1}

^a Institute of Clinical Biology and Metabolism, c) Postas 13, 01004 Vitoria, Spain

^b Department of Physiology, School of Medicine, University of Santiago de Compostela, Spain and Scientific Director of Foltra Medical Centre, Teo, Spain

^c Al-Ghad International Colleges for Applied Medical Sciences, Al-Madinah Al-Munawarah, Saudi Arabia

^d Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Via E. Orabona 4, 70125 Bari, Italy

^e Research and Development, Medical Centre Foltra, Teo, Spain

^f School of Veterinary Medicine and Science, University of Nottingham, College Road, Sutton Bonington, LE12 5RD, UK

^g Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, SLFPB-EHU, 01006 Vitoria, Spain

^h BTI Biotechnology Institute ImasD, S.L. C/Jacinto Quincoces, 39, 01007 Vitoria, Spain

ⁱ Inserm UMR1069, University François-Rabelais of Tours, 10 Boulevard Tonnellé, 37032 Tours, France

^j Institut Universitaire de France, 1 Rue Descartes, Paris 75231, France

ARTICLE INFO

Article history:

Received 19 December 2016

Accepted 6 February 2017

Available online 11 February 2017

Keywords:

Cellular acidification in cancer treatment

Cellular acidifiers

pH, NHE, cancer and neurodegenerative diseases

Ion channels in cancer and neurodegeneration

Growth factors in cancer and neurodegenerative diseases

ABSTRACT

“Wisdom is to walk in two opposite directions at the same time”

Lao Tse

During the last few years, the understanding of the dysregulated hydrogen ion dynamics and reversed proton gradient of cancer cells has resulted in a new and integral pH-centric paradigm in oncology, a translational model embracing from cancer etiopathogenesis to treatment. The abnormalities of intracellular alkalization along with extracellular acidification of all types of solid tumors and leukemic cells have never been described in any other disease and now appear to be a specific hallmark of malignancy. As a consequence of this intracellular acid-base homeostatic failure, the attempt to induce cellular acidification using proton transport inhibitors and other intracellular acidifiers of different origins is becoming a new therapeutic concept and selective target of cancer treatment, both as a metabolic mediator of apoptosis and in the overcoming of multiple drug resistance (MDR). Importantly, there is increasing data showing that different ion channels contribute to mediate significant aspects of cancer pH regulation and etiopathogenesis. Finally, we discuss the extension of this new pH-centric oncological paradigm into the opposite metabolic and homeostatic acid-base situation found in human neurodegenerative diseases (HNDDs), which opens novel concepts in the prevention and treatment of HNDDs through the utilization of a cohort of neural and non-neural derived hormones and human growth factors.

© 2017 Elsevier Ltd. All rights reserved.

Contents

1. Introduction. A brief historical account of cancer-related homeostasis 158
 - 1.1. Ion channels as a transversal bridge between oncology and research into neurodegeneration 159
2. Rationale. Proton transport and pH dynamics as an approach to cancer etiopathogenesis and treatment: The fundamental cause of Cancer? ... 159
3. Searching for universal root-mediating mechanisms of pH-related carcinogenesis 160

* Corresponding author at: Institute of Clinical Biology and Metabolism, c) Postas 13, 01004 Vitoria, Spain.

E-mail address: salvaszh@telefonica.net (S. Harguindey).

¹ These authors contributed equally to the work.

4.	Going after NHE1: further along the new anticancer road	161
5.	Anticancer and other diseases potential of the new and potent NHE inhibitors. Cellular acidification and apoptosis	161
6.	pH dynamics and multiple drug resistance (MDR): an integral approach.....	162
7.	An integral interpretation of the Warburg effect for a selective antimetabolic approach to cancer therapy.....	162
8.	pH and the Warburg effect in therapeutics	163
9.	Non-proton transport intracellular acidifiers with strong anticancer properties	164
9.1.	Salinomycin	164
9.2.	Valinomycin.....	164
9.3.	Niclosamide.....	164
9.4.	Disulfiram.....	164
9.5.	Lovastatin	164
9.6.	Non-steroidal anti-inflammatory drugs (NSAIDs).....	164
9.7.	Metformin.....	165
9.8.	Perillyl alcohol (POH)	165
9.9.	3-Bromopyruvate (3BP).....	165
9.10.	Dichloroacetate (DCA).....	165
9.11.	Nigericin	165
9.12.	Hyperthermia and radiation and the NHE1-pHi relationship	165
9.13.	Docosahexaenoic acid (DHA) and polyunsaturated Omega-3 long-chain fatty acids	165
9.14.	Cardiac glycosides	165
9.15.	Urocanic acid	166
9.16.	Photodynamic acidification	166
10.	Ion channels in cancer and neurodegeneration	166
10.1.	A) Relationships between deregulated tumor pHi/pHe and voltage-gated ion channels in cancer	166
10.2.	B) Relationships between pH, NHE1 and the voltage-gated sodium channels in cancer.....	166
10.3.	C) Ca ²⁺ homeostasis and NHE1	167
10.4.	D) Relationships between pH and ion channels in neurodegeneration	167
11.	Cell death and neuroprotection in HNDDs. A transversal extension from the pH-centric translational cancer paradigm to the etiopathogenesis and therapeutics of neurodegeneration.....	168
11.1.	The pH-centric cancer paradigm in HNDDs. Is the intracellular pH a key homeostatic factor for understanding and treating human neurodegenerative diseases?	168
12.	Growth factors and melatonin in HNDDs and cancer. Lack of trophic factors leads to decreased trophism and mobility.....	169
12.1.	A) Deficiencies of human Growth Factors (hGFs) and other hormone deficiencies in HNDDs.....	169
12.2.	B) Human growth hormone (hGH) and melatonin (MT) in HNDDs and cancer. A beneficial side-effect of the new therapeutic trends?	169
12.2.1.	I – hGH in HNDDs	169
12.2.2.	II – Melatonin (MT) in HNDDs	170
12.2.3.	III – Melatonin (MT) as an oncostatic and cytotoxic agent	170
12.3.	C) Neural and platelet-derived human growth factors (PDGFs) in the treatment of HNDDs	170
13.	Conclusions.....	171
	Conflicts of interest.....	171
	Funding.....	171
	Acknowledgments	171
	References.....	171

1. Introduction. A brief historical account of cancer-related homeostasis

In the 1920's, Claude Bernard had created the philosophical and physiological concept of the *milieu interieur* [1,2]. Walter Cannon followed with a similar idea and terminology to initiate the first studies on homeostasis. From these seminal considerations the concept of homeostasis was extended to include acid-base homeostasis [3]. These precedents inspired Hans Selye to create his famous General Adaptation Syndrome [4]. While the term homeostasis initially referred to a balanced, dynamic and systemic physiological situation, the term allostasis refers to multiple interactions between the body and cellular systems to maintain a physiological stability, given that some of those systems can become overactivated or dysregulated [5,6]. These classical medical visions, that considered all body systems and the organism as a whole, inspired our interest on how the hierarchical organization of physiopathological acid-base systemic deviations could be applied to cancer biology. In that vein, we initially referred to the cancer situation as a “chronic anti-adaptation syndrome”, a parallel concept of allostasis [7], and showed the existence of a systemic alkalotic acid-base deviation of the blood of patients with different solid tumors [8].

During the last few years and after one hundred years of metabolic cancer research following the seminal findings of Otto Warburg [9], there has been a fast and growing interest on the dysregulation of proton [H⁺]-related mechanisms, which underlie the initiation and progression of the neoplastic process [10–17]. This new pH-centric paradigm of cancer is based upon the fact that all cancer cells and tissues have a pivotal energetic and homeostatic/allostatic disturbance of their metabolism that is completely different from all normal tissues. This is an aberrant regulation of hydrogen ion dynamics leading to a reversal of the normal intracellular/extracellular pH gradient (↑pHi/↓pHe, or “proton gradient reversal”, PGR) [18,19], where malignant intracellular alkalization has become a selective and specific hallmark of cancer intracellular homeostatic failure, in both solid tumors and leukemias, since it has not been described in any other disease process [18].

This PGR of the cancer cell is associated with the origin of the malignant process and with cellular transformation, proliferation, local growth, motility, migration, activation of the metastatic process, resistance to chemotherapy and with the phenomenon of the spontaneous regression of cancer [18,20]. Therefore, measuring intracellular pH (pHi) in tumors seemed to be essential for the monitoring of cancer progression and the response of cancer cells

to various treatments. This is why new methods to determine pHi in tumors have been developed [21]. On the other hand, attempts to control and reverse the extracellular/intratumoral acidification have been thought to represent a viable therapeutic approach to control tumor growth and the metastatic process. To this end, proton pump V-ATPase inhibitors (PPI) were initially proposed and have been later used in preclinical and clinical studies, but not always successfully when associated to chemotherapy [20,22–27], as well as in the overcoming of resistance to certain chemotherapeutic drugs [23]. Also, the utilization of alkaline diets using bicarbonate or other buffer infusions have been tried but proved not to be feasible in bedside oncology, either because toxicity or lack of effect [28,29]. These studies illustrate why it is important to take into account that tumor interstitial acidity is a consequence of a pathological induction of intracellular alkalinity as a result of proton transport extrusion driven by up-regulation of one or more of membrane-bound proton transporters (PT) [9]. This is the reason why we support a more etiological, and thus radical therapeutic approach rather than struggling directly against the extracellular acidification of malignant tumors, which at the most it will be a collateral and beneficial side-effect of this new pH-centric approach to cancer treatment. The idea is to induce a selective intracellular acidification of cancer cells by blocking acid extrusion through the utilization of pharmacological dosages of a cohort of proton transport inhibitors (PTIs) [30] and/or other non PT-derived cell acidifiers with known anticancer properties (see later sections). Furthermore, PTIs would decrease the extracellular/intratumoral acidification of malignant tumors and reverse the tumor-selective malignant PGR known to stimulate local invasion and the metastatic process. Thus, intracellular acidification becomes fundamental in any attempt to induce a selective apoptosis of malignant cells [31–34]. In this review, we will analyze the different classes of anticancer drugs currently available to induce cellular acidification as a new approach to the treatment of cancer.

1.1. Ion channels as a transversal bridge between oncology and research into neurodegeneration

Ion channels contribute in the mediation of important aspects of both cancer and neurodegeneration, among which pH regulation is a fundamental one. This makes the knowledge of ion channel physiopathology a useful tool for bridging research between oncology and neurology. Its study also permits the translation of the pH-centric paradigm from the cancer field to some fundamental aspects of the etiopathogenesis and treatment of human neurodegenerative diseases (HNDDs). This widening of perspective from oncology to HNDDs is developed here as an attempt to embrace two otherwise widely separated areas of research within one encompassing and integrated vision (*transversal research*) [35]. This new approach is based upon the fact that these two situations are apparently opposite regarding cellular acid-base and H⁺-related cellular homeostatic balance: an alkaline pHi that occurs in malignancy (high pHi-mediated anti-apoptosis or *pathological anti-apoptosis*) while an acidic pHi occurs in certain HNDDs like Alzheimer's disease (AD) (low pHi-mediated “spontaneous” apoptosis or *pathological apoptosis*) (Table 1) [35–39]. Therefore, on the basis of the dynamics of the hydrogen ion (H⁺) both situations belong to opposite ends of a metabolic spectrum that determine the fate of cells in cancer and HNDDs. Finally, this integrated homeostatic perspective can also open novel strategies for the prevention and treatment of HNDDs through the use of a cohort of human growth factors (hGF) and hormones that increase pHi and stimulate cellular metabolism by activating some of the alkalizing proton transporters, mainly the Na⁺/H⁺ exchanger (NHE), that are over-expressed or over-activated in cancer (Fig. 1).

2. Rationale. Proton transport and pH dynamics as an approach to cancer etiopathogenesis and treatment: The fundamental cause of Cancer?

The primary phenomenon that leads to a reversed hydrogen ion gradient in cancer metabolism is the pathological regulation of hydrogen ion dynamics of malignant cells and tissues ($\uparrow$ pHi/ $\downarrow$ pHe) [11,18,19,40] (Table 1). Seminal research in this area first demonstrated that the stimulation of the Na⁺-H⁺ exchanger isoform 1 (NHE1) was fundamental to oncogene-driven neoplastic transformation. The activation of NHE1 stimulates proton extrusion with a resultant intracellular alkalization and extracellular acidification [41]. This cytosolic alkalization was shown to be the primary driver of a series of transformation hallmarks, namely, increased growth rate, substrate-independent growth, growth factor independence and glycolysis in aerobic conditions and tumor growth [41,42]. In addition, it has been demonstrated that some oncogenes utilize NHE1-induced alkalization to induce the cancer specific pH dysregulation of cancer cells [19,43]. However, from pH-driven transformation to tumor growth and metastatic progression in different malignant tumors can also be mediated by the overexpression and/or overactivation of other PTs like monocarboxylate transporters (MCTs) [44–51].

In the same vein, a direct cause-effect relationship between the elevation of pHi in cancer and the multiple drug resistance (MDR) phenotype has also been described by different research groups [52–56]. Indeed, the failure to kill tumor cells following chemotherapeutic treatment appears to be highly dependent on their resistance to undergo intracellular acidification, a situation that is apparently necessary as a prior condition that forces cancer cells to engage in a tumor-specific apoptotic or para-apoptotic processes [31,33,57]. This is part of the defensive anti-apoptosis strategy of all types of cancer (“the neostrategy of cancer cells and tissues”) [18], known to be mediated by multiple and different cellular anti-acidifying mechanisms [53,58–60].

Recently, it has been demonstrated that H⁺ efflux alone is sufficient to induce dysplasia and potentiate growth and invasion by oncogenic Ras and, furthermore, that inhibiting this H⁺ efflux produced cell death in invasive primary tumor cell lines that was related to a secondary mitochondrial depolarization [61]. Similar results have been obtained by the group of Fliegel, showing that NHE-mediated H⁺ extrusion by itself has a carcinogenic effect on breast cells [62,63]. In these studies, NHE1 hyperactivity appears to be an early and decisive driver in breast cancer carcinogenesis [42]. Furthermore, an increased pHi and increased proton efflux with a secondary acidified microenvironment has been implicated in the transition and progression from precancerous ductal carcinoma *in situ* to invasive breast cancer, with the precancerous lesion already showing a higher than normal proton export rate [64]. We agree with the conclusion that H⁺ efflux is the main and final cause of breast cancer, independently of the many other mediating factors that can be involved in the development of this cancer. Moreover, this seems primary to the fact that a very acidic

Table 1
pHi and pHe in normal and cancer cells: apoptosis and antiapoptosis.

NORMAL CELLS	CANCER CELLS
(pHi < pHe)	(pHi > pHe)
Intracellular pH (pHi) 6.99–7.05	(“proton gradient reversal”) (PGR) Intracellular pH (pHi) 7.2–7.8
Extracellular/interstitial pH (pHe) 7.35–7.45	Pathological antiapoptosis Extracellular/interstitial pH (pHe) 6.2–6.8 Therapeutic apoptosis

*For further details, see text and refs [9,15].




Fig. 1. The role of human growth factors (hGFs) and growth hormone (hGH) on NHE and on cellular metabolic stimulation. The possibility of malignant transformation after treatment with hGH [403–405] or PDGF [406] has been raised but has not been shown in regenerative medicine [407]. On the contrary, lack of hGFs and/or hGH keeps levels of cell metabolism very low and induces cellular acidification and apoptosis. For more information see text and references [35,354,357–359,366,370,373,380]. Abbreviations: VEGF: Vaso endothelial growth factor; IGF-1: Insulin growth factor 1; FGF: Fibroblast growth factor; PDGF: Platelet-derived growth factors; EPO: Erythropoietin; EGFR: Endothelial growth factor receptor; NGF: Nerve growth factor.

extracellular microenvironment secondary to proton transporters (PTs)-mediated H^+ efflux is known to be a specific hallmark of all malignant tumors [11,12,19,61,65]. In these very hostile conditions, cancer cells of all tissue origins and showing different genetic alterations defend themselves from highly toxic microenvironment by activating H^+ efflux through a series of proton pumps, exchangers and transporters [11,19,22,66]. Thus, the induction of a selective intracellular acidification of cancer cells with PTIs and/or PPIs [22] in-order-to block different PTs, either singly [67–70] or simultaneously [30], and/or with other cell acidifying molecules of different origins and natures is increasingly becoming a promising choice in a new and different attitude towards modern cancer chemotherapeutics [9,13,33,71–76].

3. Searching for universal root-mediating mechanisms of pH-related carcinogenesis

A cancer-specific intracellular alkalosis represents a common final pathway in cell transformation and an anti-apoptotic defensive mechanism in cancer cells. This has been demonstrated to be induced by a myriad of factors. These include the overexpression/hyperactivity of different PTs apart from NHE [11,19,49,51,77–84] and PPs [85], the MDR promoting effects of certain oncogenes, virus and viral proteins, gene products, like Bcl-2 [58,86], a dysfunctional p53, various growth and/or trophic factors (GFs) [87–91] and a number of chemical carcinogens. Other carcinogenic NHE-related factors are chronic hypoxia and hypoxia-inducible factor (HIF) [66,92], different hormones and even high glucose loads [93] (Table 2 and Fig. 1).

Importantly, if a myriad of unrelated factors coming from many different origins and natures are carcinogenic, we are constrained to hypothesize that the hyperactivity of NHE1 and its pH_i raising ability, as well as the overexpression of other PTs, may constitute a general phenomenon that can perhaps be extended to many other unidentified carcinogenic factors. This seems to suggest “a universality of phenomenon involved in human carcinogenesis” (Table 2) [41,58,59,87–89,94–98]. Or, in other words, as Otto Warburg wrote

Table 2

Factors that increase cell pH and/or stimulate NHE activity as mediators of high pH_i -mediated carcinogenicity.

Proton transporters (PTs) and proton pumps (PPs)
Virus (HPV E5, human polioma virus)
Oncogenes and viral proteins (v-mos, Ha-Ras, HPV16 E7)
Gene products (Bcl-2)
p53 deficiency
Genetic instability
Chemicals carcinogens (arsenic salts, benzo(a)pyrene)
Chronic hypoxia and HIF
Different mitogens
Hormones and cytokines (Insulin, growth hormone, prolactin, glucocorticoids, IGF-1, EGF, VEGF, PDGF, IL-1, IL-8, G-CSF, TGF- β , Angiotensin II, PGE2, Bombesin, Diferric transferrin)
Glucose overload
Time (ageing)

*Modified from Harguindey et al. [9]. For further details, see text.

concerning his famous, however controversial, “damaged respiration” theory [99] on the primary cause and origin of cancer: “there are uncountable secondary causes: almost everything causes cancer, even time” [100,101]. This statement by Warburg saying that even “time” causes cancer seems to be confirmed by recent research showing that NHE activity increases during ageing in humans [102]. Finally, environmental acidification, mediated by overexpression of either NHE and/or other PTs, is known to play a role in hindering DNA repair, increasing mutagenesis and driving genomic instability in cancer [103–111]. Thus, the acidic pH_e role in genomic instability can be considered as the last step in closing the vicious cycle of a single and multidimensional process ending up in a very dynamic and highly self-organized chaos (“the neostrategy of cancer cells and tissues”) [9,18].

Incidentally, some recent reviews on environmental carcinogenesis have not taken into consideration this association between pH /NHE1/PTs and environmental carcinogenesis [112,113]. However, other groups have paid close attention to these observations [96]. Finally, DNA damage has also been associated with NHE1 expression, intracellular alkalization and Bcl-x1 deamidation, this

preceding apoptosis in different tumor cell lines. No matter that this may seem to be a paradox at first sight, since cell alkalinization has rarely been associated with apoptosis [114], this association can also help to link the new pH-centric paradigm with the classical DNA-paradigm in cancer research and treatment.

4. Going after NHE1: further along the new anticancer road

Indeed, as described above, it is well established that there is an increased expression and/or activity of one or more of the pH regulators in most or all cancer cells of different origins [19,46,72,115,116]. Among all the known pH regulators, the Na^+/H^+ exchanger type 1 (NHE1) has drawn a lot of attention because not only is it overexpressed but also over-activated in many kinds of cancer cells, from breast to ovary [42,63,65,117,118]. Besides, its hyperactivity is associated with cancer cell survival, migration, invasion and metastatic progression [65,119]. NHE1 catalyzes the electroneutral exchange of H^+ and Na^+ , driven by the inwardly directed electrochemical Na^+ gradient [120], and it is ubiquitously expressed at the plasma membrane of all mammalian cells. It is considered to be a “house-keeping” intracellular H^+ regulator, protecting normal cells from intracellular acidification [121]. NHE1 is quiescent at physiological pHi ($\text{pHi} \geq 7.2$), but its activity increases rapidly upon intracellular acidification following a dimeric Monod-Wyman-Changeux cooperative mechanism [122]. Its activity is tightly regulated and its sensitivity to pHi is increased in situations that can be found in the context of cancer, such as when it is activated by growth factors, hormones, different mitogens and environmental carcinogens [123–125] (Fig. 1). Finally, it is also involved in cancer cell motility and matrix degradation [126,127] despite a relatively low alkalinized pHi [65]. For all these reasons, during the last few years NHE1 has become a very important target in selective cancer therapeutics [9,67,71,86,115,128–131]. Most recently, inhibition of NHE1 and cancer proton reversal have been correctly regarded as the latest concept in cancer treatment [22,30,51,132,133].

5. Anticancer and other diseases potential of the new and potent NHE inhibitors. Cellular acidification and apoptosis

Decreasing NHE1 expression or inhibiting its activity leads to hyperacidification of the intracellular space, inhibition of glycolysis, tumor cell growth arrest and selective apoptosis [33,134,135]. Indeed, it has been shown that cariporide (CP, HOE 642), a selective and potent NHE1 inhibitor, reduces proliferation and induces apoptosis through a decrease of intracellular pH and induces apoptosis in cholangiocarcinoma cells [136]. While intracellular acidification inhibits the expression of vasoendothelial growth factor (VEGF) when NHE is inhibited [137], cariporide also inhibits angiogenesis and the growth of leukemia cells by inhibiting the Na^+/H^+ exchanger, [138]. Cariporide has also been proved to be useful in overcoming metastatic progression and multiple drug resistance (MDR) [139].

Furthermore, in combination with inhibitors of the Na^+ -dependent Ca^{2+} transporter, cariporide induces a non-apoptotic death in glioma cells [140]. In the same line, cariporide acts synergistically with erlotinib in reducing growth and invasion of pancreatic ductal adenocarcinoma (PDAC) [141]. Regarding cariporide, it is most surprising that it has not raised any interest to facilitate its preclinical and/or translational research in the field of oncology, more if its international patent literally reports that “there is a surprising prolongation of life of cancer in the elderly to an extent which has to date been achievable by no other group of drugs or by any natural products. This is a unique effect of NHE

inhibitors like cariporide (CARIPORIDE PATENT WO2004007480, SANOFI-AVENTIS, 2005).

Importantly too, the 5-aryl-4-(4-(5-methyl-1*H*-imidazol-4-yl) piperidin-1-yl) pyrimidine analog (compound 9t) was reported to be 500-fold more potent against NHE1 than cariporide and to have a greater selectivity for NHE1 over NHE2 (1400-fold) [142]. Additionally, compound 9t is orally bioavailable, has low side effects in mice and shows a significantly improved safety profile over other NHE1 inhibitors (BRISTOL-MYERS SQUIB PATENT WO 01 27107 A2, PCT/US00/27, 2001, US 6887870 B1; EP 1224183 B1). Surprisingly too, this drug has never been tested as an anticancer drug to date and, somehow, has been lost “missing in inaction” due to a lack of further interest by the discoverers and/or patent holders concerning its possible utilization in preclinical and/or clinical oncology and in spite of its most promising antitumoral characteristics and selective anticancer potential.

Another potent and selective NHE1 inhibitor, the aminophenoxazine derivative Phx-3, has been shown to trigger apoptosis in a variety of cancer cell lines. In animal models, Phx-3, effectively and without noticeable toxicity reversed tumor growth after subcutaneous injection of adult leukemia cells [31,57]. In any case, these new and selective NHE1 inhibitors show a great potential to become potent anticancer agents in preclinical trials and, eventually, in cancer patients. At the present time, research along this line in different malignancies shows that several PTs and their inhibitors are very selective as diagnostic, predictive and potential anticancer agents [54,69,143].

On the contrary, while decreasing intracellular pH induces a cell death program (CDP), apoptotic, para-apoptotic or necrotic, in malignant cells, the elevation of cellular pH by different methods protects cancer cells by preventing them from entering the apoptotic cascade. In this case too, this suggests a universality of phenomenon concerning the role of pH in cell fate [144]. Interestingly, clinical trials using the new NHE inhibitor rimeporide are being conducted in neuromuscular processes like Duchenne Muscular Dystrophy, the only disease outside the cancer context where a high pHi has been shown to be involved in its pathogenesis [145,146]. In terms of mechanisms, it is known that decreasing intracellular pH induces a cell death program, either via apoptosis, para-apoptosis or necrosis, while the elevation of cellular pH by different methods protects cancer cells by preventing them from entering the apoptotic cascade. On the low pHi therapeutic-apoptotic side, striking results in leukemia cells were initially reported with the amiloride derivative and potent NHE1 inhibitor 5-(*N,N*-hexamethylene) amiloride (HMA). This compound decreases the pHi below the survival threshold leading to selective apoptosis in a variety of human leukemic cells [33]. An increasing number of later studies in the same line have led to the conclusion that inducing a low pHi-mediated apoptosis can be a cancer-specific therapeutic strategy for all cancer cells and tissues [13,35,62,68,69,134,137,147–152]. Most recently, HMA has shown selective cytotoxicity to breast cancer cells irrespective of their molecular profile, proliferative status or species of origin, suggesting a necrotic cell death mechanism common to all mammary tumor subtypes [153]. Moreover, acting not only on NHE1 but also on other PTs leads to a significant control of malignant growth and tumor angiogenesis, also showing an important role in the overcoming of MDR [137,138,154–157]. The final aim should be to target the selective acid-base disruption of cancer cell metabolism based on the H^+ -dependent thermodynamic advantages that malignant cells possess over their normal counterparts, in order to exploit such differences in selective cancer therapeutics.

Interestingly, Marches et al. elegantly showed the intimate link between cancer biochemistry, molecular biology and cancer-related immunity by demonstrating that the anti-IgM-mediated induction of cell death in human B lymphoma cells is dependent

Table 3
pHi, apoptosis and antiapoptosis in HNDDs and cancer.

HNDDs	Cancer
↑ pHi Therapeutic antiapoptosis	Pathological antiapoptosis
↓ pHi Pathological apoptosis	Therapeutic apoptosis

on NHE1 inhibition and subsequent intracellular acidification. This important publication conceptually unified three different fields of oncology research: biochemistry, molecular biology and cancer immunity under one wider embracing unit [52,158]. The concerted utilization of PTIs as a primary cancer treatment, as well as an adjuvant measure in overcoming MDR, has been advanced by our group in several publications approached from different perspectives, ranging from basic physics to bedside therapeutics [35,52,133,159]. A successful, etiological/radical treatment in cancer would thus be mediated by the activation of an acidic pHi-mediated apoptotic chain reaction cascade ending in cancer cell death (*therapeutic apoptosis*) (Tables 1 and 3). Finally, preliminary trials in a clinical setting using different PPs and PTIs, either on their own or associated with chemotherapy, have been recently published in basic studies [141], animal models [160,161] and humans patients with cancer [22,133,161–164]. However, some recent studies have shown a negative effect of the combination of certain chemotherapy protocols with proton pump inhibitors [27,165].

6. pH dynamics and multiple drug resistance (MDR): an integral approach

Historically, there have been different theories concerning MDR in cancer. The first one that was put forward stemmed from basic pharmacokinetics and the impact of protonation in drug uptake into the body from the acidified stomach. This theory states that low extracellular pH should oppose drug uptake since drug protonation impedes their transmembrane movement across the cellular bilayer membrane, especially if the drugs are weak bases, such as doxorubicin (pKa ~ 8) [23,56,166]. While this can apply to weak bases, the pH gradient should not interfere with drugs that are weak acids or neutral. To understand the efflux of drugs in these cases, a P-glycoprotein (P-gp)-mediated resistance was then suggested. Initially, the P-gp approach to justify MDR seemed to fit with all the most important aspects of biochemistry. However, little attention had been paid until recently to the fact that drug-handling via P-gp also needs a pH gradient to function. So, the question as to whether and how the drugs come into contact with P-gp to be expelled has remained open for a long time. Furthermore, the ability of P-gp to handle, literally, almost hundreds of chemically different compounds challenges the notion of specificity (defined as very high affinity). Indeed, how a single glycoprotein can interact so efficiently with all those chemically different compounds is at least paradoxical.

To resolve this and other issues, a more integrated mechanism to explain MDR has been recently developed. This is based upon the modification of the dynamics of the tumor microenvironment through changes in the extracellular and intracellular pH [54,55,95,167–174]. This model highlights the impact of the pH gradient in P-gp expression [175]. It has been demonstrated that the pH gradient stiffens cell membranes, constraining drugs to remain trapped within them for longer times, thereby increasing the probability of drug-P-gp interactions followed by extrusion [166,172,173,176]. In this context the term “stiffening” refers to an imbalance between lipid interaction forces due to a pH change (Fig. 2). From a parallel therapeutic perspective of pH-related resistance to therapy, the specific acid-base abnormalities of cancer metabolism significantly contribute to decrease, and even completely block, any immune reactivity against malignant tumors

[177]. In all these cases, the therapeutic failure to induce cytoplasmic acidification and/or reverse PCR has been proposed to be the main underlying factor for MDR, because it also means resistance to the induction of the low pHi-mediated therapeutic apoptosis in either normal, slightly alkaline and/or highly alkaline cancer cells [18,58,150,151]. The expression of P-gp leading to an elevation of pHi also correlates with a decreased plasma membrane potential in cancer cells, an electrical change that for a long time has also been regarded as a potent mitogenic and carcinogenic stimulus [178]. This is apparently due to a pH-related P-gp overexpression and not to exposure to chemotherapeutic drugs [179,180]. In line with this hypothesis, P-gp mediated resistance to imatinib in BCR-ABL-positive leukemia is reversed by NHE1 inhibitors like cariporide [181]. Similarly, intracellular acidification both decreases P-gp resistance in leukemia cells with high P-gp expression while also increases the cytosolic accumulation of drugs like doxorubicin [182]. Further, P-gp expressing cancer cells exhibit a significantly higher pHi than non-P-gp expressing cells, which to a certain degree accounts for the P-gp-mediated resistance [52]. Indeed, the fact that cells with an active P-gp transporter show a high degree of cytoplasmic alkalization has led some authors to conclude that P-gp can be mainly considered as a proton extrusion pump [159,168,171,183]. Finally, intracellular acidification down-regulates P-gp, while extracellular acidification increases the activity of P-gp and induces MDR in rat prostate cancer cells and tissues [184] as well as in other tumors [185].

7. An integral interpretation of the Warburg effect for a selective antimetabolic approach to cancer therapy

Another unique hallmark of cancer cells is their shift to glycolytic metabolism over oxidative phosphorylation (OxPhos), even under aerobic conditions. This was first described by Otto Warburg [186] and it is known as the Warburg Effect [100,101].

During the last decade, the number of publications that explain the Warburg effect and how it functions have increased dramatically. However, apart from considering its early role in oncogenesis, a full explanation of the dynamics of its development in cancer cells and how it leads to cancer is still unresolved [187]. Early experiments of controlled oncogene activation showed that the first appearance of glycolytic metabolism occurs very early in the oncogene-driven transformation of normal cells and that its development was dependent on the initial oncogene-dependent cytoplasmic alkalization [188,189]. Indeed, as both the processes of OxPhos and glycolysis are exquisitely but oppositely pH sensitive, a rapid shift of cell metabolic patterns follows alkalization. No matter that these concepts belong to the new pH-centric paradigm, a discussion of the effects of acid-base changes on glycolysis and the dependence of the metabolic balance between glycolysis and oxidative phosphorylation on pH was already described more than four decades ago. However, at that time there was the exclusive emphasis on a physiological and not on an oncological perspective [190].

Besides, there is increasing evidence that both pHi and pHe are important in driving this ever increasing dependence on glycolysis and decreasing dependence on OxPhos as the tumor progresses [134,191]. Indeed, as both the processes of OxPhos and glycolysis are exquisitely but oppositely pH sensitive, a rapid shift of cell metabolic patterns follows alkalization. Besides, a great deal of evidence supports the fact that it is the alkaline pHi present in cancer cells which is the primordial driver of this metabolic shift, and that this change is one of the ‘corner-stones’ in the altered metabolism underlying neoplastic transformation and progression and such reciprocal metabolic shift may well be one of the most sensitive pHi sensors of a cell. This adds further weight to the current




Fig. 2. Effect of pH on lipids packing.

(A) Assuming a leaflet composed of charged lipids. The optimal area per lipid is determined by the competition between an attractive energy that reflects lipids attraction linked to their hydrophobic tails and a repulsion energy, which we will assume to be linked to a net charge carried by all the lipids. The competition between these two defines a minimum of energy. Note that in the figures, a_0 corresponds to the optimal distance between adjacent lipid heads.

(B) Thus the minimum of energy provides the optimal distance between lipids including their optimal area in the monolayer. Note that the packing of lipids is not always defined by hard core contact/steric repulsion and that, accordingly, there is room to change this packing.

(C) With regard to negatively charged lipids, an increase in the concentration of hydrogen ions allows more of them to interact with lipids' head. Thus by masking their negative charges, the long-range repulsion between lipids is disturbed. The resulting effect will be an alteration of the positioning of the minimum energy, which will move closer to the lipids.

(D) Top view of a portion of a membrane. The lipid's hard core head is colored in red and the optimal area per lipid driven by repulsive/attractive interactions, is drawn in blue. Changes in pH are expected to redefine the optimal area per lipid and thus their packing. In the figure, a decrease in the pH is represented. In conclusion, a low cytosolic pH is expected to decrease the surface area per lipid (Modified from Rauch [176]).

opinion that among the uncountable allosteric factors that regulate the glycolytic sequence, the intracellular pH (pHi) is by far the most decisive one [71]. Indeed, recent publications also lead to the conclusion that the Warburg Effect may be completely explained through the elevation of pHi in cancer cells [31,57,71,192].

Lower extracellular pH (pHe) (in both the presence and absence of extracellular lactate) also shows profound effects on tumor cell gene expression, including genes involved in glycolysis [103]. Furthermore, the inhibition of NHE1 results in changes in the expression patterns of a number of genes including many that regulate cellular metabolism [193]. Recently, the relationships between pH and every step of the glycolytic chain, as well as the metabolic changes relating pH, glycolysis and the pentose phosphate pathway and their respective roles in tumor metastasis have been thoroughly reviewed [71,194]. Therefore, these complex dynamics of the role of pH in intermediary metabolism starts with the first oncogene-driven pHi change and it is this very early alteration of pH dynamics and the consequent metabolic disruption, which sets the stage for the conditions necessary for tumor growth and metastatic progression, further illustrating the pH-centric paradigm for carcinogenesis and metastasis.

Interestingly, neoplastic progression is considered to be the result of a clonal selection of increasingly more aggressive cells. However, the accumulation of genetic defects resulting in malignant cells is faster than theoretically predicted. Recently, this contradiction has been solved with the observation that the tumor microenvironment drives the selection of aggressive cells within a tumor by contributing to tumor genetic instability [104–106]. Thus, cancer is a prototype of the paradigm of a positive feedback of genotype and phenotype interactions in which the resulting

phenotype from the initial genotypic alteration promotes further genotypic alterations in a self-fed vicious and thermodynamically-advantage cycle [43]. This fundamental role of pH regulation (driven by NHE1 and other proton transporters) in modulating cellular metabolism is perhaps not surprising considering the postulated role of an ancient NHE together with ATP synthase in the origin and development of chemiosmotic coupling and bioenergetics [195]. Indeed, the proper functioning of mitochondrial OxPhos metabolism is dependent on a high, constant and finely regulated cytosol-mitochondrial proton gradient [43,196,197].

8. pH and the Warburg effect in therapeutics

2 From the therapeutic point of view, inhibiting tumor glycolysis [198] and reversing the Warburg effect by selective intracellular acidification has already been considered as a treatment in cancer therapeutics [31,95]. Indeed, in the light of both older and more recent contributions [19,31,199,200] it can be concluded that counteracting the Warburg effect and aerobic glycolysis to selectively induce intracellular acidification and/or reverting PGR in cancer cells now appears to represent the same phenomenon [9,31,57]. This advances a rational and firmly based approach to cancer treatment of all malignant tumors. In summary, the most potent and promising amiloride and non-amiloride derivatives, such as Cariporide, Phx-3 and compound 9t [57,71,142] need to be urgently included in pre-clinical and clinical trials as an important part of the anticancer armamentarium, either alone as single anticancer drugs and/or associated to other synergistic methods and therapies, such as antiangiogenics [137,138]. In addition, the most potent NHE1 inhibitors, as well as other PTI inhibitors, should be consid-

ered as chemotherapeutic agents on their own, since they are able to induce intracellular acidification and/or reverse the abnormal PGR of cancer cells and tissues. It can be advanced that they show a great promise as a new and selective approach to the treatment of a wide array of different malignant tumors, even leukemias, and their use in bedside oncology should help to overcome the present impasse and flat progress in cancer treatment [201].

9. Non-proton transport intracellular acidifiers with strong anticancer properties

There is a large family of cellular acidifiers not directly related to PTI that have shown strong anticancer properties and will be now considered as a group for the first time.

9.1. Salinomycin

Salinomycin is a K^+ ionophore antibiotic isolated from *Streptomyces albus* known to have a strong anti-cancer activity. Salinomycin kills cancer stem cells in different types of human cancers by interfering with ABC drug transporters, the Wnt/ β -catenin signaling pathway, mitochondrial function and other CSC pathways [202,203]. By comparing the chemical structures and cellular effects of this drug with those of valinomycin (K^+ ionophore) and nigericin (K^+/H^+ exchanger), these authors concluded that salinomycin mediates K^+/H^+ exchange across the inner mitochondrial membrane. Clinically, this drug has been able to induce partial regressions of heavily pretreated and therapy-resistant cancer patients [204]. The antitumor mechanisms described for salinomycin activity include the efflux of intracellular K^+ and a reduction of pHi, an increase in intracellular Ca^{2+} and a down-regulation of MDR. Such antitumor mechanisms are connected to its strong affinity especially to potassium cations. Salinomycin promotes the outflow of K^+ from the mitochondria as well as cytoplasm, and similar to other ionophores mediates in a H^+/K^+ exchange across lipid membranes. This in turn leads to an increase in intracellular Ca^{2+} and a down-regulation of MDR [205]. However, the inhibition of mitochondrial Na^+/Ca^{2+} -exchangers (NCX) by CGP-37157 was shown to inhibit the mitochondrial Ca^{2+} accumulation induced by Salinomycin, while maintaining its antineoplastic efficacy [206]. While this approach indicates a route to reduce or prevent salinomycin-induced neuropathy, it also rules out a main potential anti-cancer mechanism, i.e. mitochondrial Ca^{2+} accumulation. The antineoplastic effect of this and other ionophores is believed to be mainly due to their ability to directly acidify the intracellular environment since DNA synthesis stops as cell pHi decreases [207], confirming a direct relationship between pH and DNA synthesis, a feature that has been known for decades [208]. Finally, it has been recently shown that the cytotoxic effect and autophagy inhibition associated with Salinomycin was dramatically enhanced in acidic conditions, cellular acidification that increases autophagic elimination of mitochondria (mitophagy), a feature that has also been proposed to underlie the pathogenesis of several neurodegenerative diseases [209,210]. Therefore, acidity around tumors may represent the fuel supporting the transfer of cations across biological membranes via K^+/H^+ exchange.

9.2. Valinomycin

Valinomycin, another K^+ ionophore, triggers a rapid loss of mitochondrial membrane potential and precedes cytoplasmic acidification in murine pre-B cell lines, which leads to cysteine-active-site protease activation, DNA fragmentation and cell death [211].

9.3. Niclosamide

Niclosamide belongs to the anthelmintic family especially effective against cestodes that infect humans. Niclosamide has been shown to exert antiproliferative activity in a broad spectrum of cancers, including acute myeloid leukaemia cells and solid tumors, like colon cancer, breast cancer and prostate cancer [212,213]. Besides the fact that niclosamide is known to hit many different intracellular signaling pathways (e.g. β -catenin, Notch, and mTORC1 pathways) [212], experiments in both breast cancer cells and cell-free systems demonstrated that this drug possesses cellular protonophoric activity by pumping protons from lysosomes to the cytosol down their concentration gradient, therefore leading to an effective lowering of cytoplasmic pH [214].

9.4. Disulfiram

The thiocarbamate alcoholism drug disulfiram, normally used to block the processing of alcohol in the body, has been shown to block the P-gp extrusion pump and to inhibit the transcription factor nuclear factor-kappaB (NFkB). In this way, it sensitizes tumors to chemotherapy, reducing angiogenesis and inhibiting tumor growth *in vitro* [215]. Disulfiram has also been shown to inhibit human melanoma growth *in vitro*, both in mice and in a patient with metastatic disease. This study also reported that, at currently approved doses for alcoholism, the combination of oral zinc gluconate and disulfiram also induced a >50% reduction in hepatic metastases and produced a long term clinical remission in a patient with stage IV metastatic ocular melanoma. While the relationship of pHi to Disulfiram is not known, an acidic tumor microenvironment enhances the cytotoxicity of disulfiram/ Cu^{2+} Antabuse complexes in MCF-7 breast carcinoma and HT-29 colon carcinoma cells [216].

9.5. Lovastatin

It has been previously shown that statins exhibits antiproliferative activity against cancer cells, representing a category of drugs available for clinical use. Recent trials show that the addition of statins to traditional chemotherapeutic protocols increases the efficacy of chemotherapy in statin-sensitive tumors [217]. It has also been demonstrated that Lovastatin (LOV)-induced apoptosis is associated with dose-dependent intracellular acidification, and this correlates with the extent of DNA degradation. Importantly, this activity was suppressed by NHE1-driven intracellular alkalization [218]. These observations provide a further connection between the activation of the NHE1 and the suppression of apoptosis seen in resistance to chemotherapy [144]. Finally, LOV, as other statins like atorvastatin and simvastatin, is known to be a MCT1 inhibitor [219].

9.6. Non-steroidal anti-inflammatory drugs (NSAIDs)

Some NSAIDs, such as Diclofenac, Diflunisal and Aspirin are also known for having anti-cancer effects. Lactate is transported out of the cancer cell by monocarboxylate transporters (MCTs) [36] and NSAIDs with monocarboxylic acid structures, such as Diclofenac, have been reported to inhibit MCTs [220]. Since Diclofenac blocks tumor cell proliferation via MYC and ciclo-oxygenase (COX)-dependent and independent mechanisms, it was concluded that Diclofenac holds a potential as a clinically applicable MYC and glycolysis inhibitor to be utilized together with established tumor therapies [220]. In this regard, a significant intracellular accumulation of lactate in cells treated with Diclofenac preceded the observed effects on gene expression, suggesting a direct inhibitory effect of Diclofenac on lactate efflux, probably through a lowering of

pHi. These results further show that lactate efflux, PGR, pH, glycolysis and tumor growth are closely related as belonging to the same integral, hierarchically organized and selective metabolic strategy of cancer [18,69,221].

9.7. Metformin

There is growing evidence for a role of metformin in tumor chemotherapy [222], for instance in breast cancer [223,224]. Metformin should be suggested as a supporting element for treatment with PTIs because it acts through on mitochondrial respiration by inhibiting the complex I of the electron transport chain, hence blocking oxidative respiration. As a result of this effect, the dependence of cancer cells on glycolysis is increased, and it can additionally be targeted with PTIs. Also, metformin may potentiate the therapeutic strategy of disrupting the export of lactate by blocking MCT1 function. Consequently this leads to an accumulation of intracellular lactate and a decrease in pHi that rapidly disables tumor cell growth and glycolysis [225,226]. Furthermore, metformin is also effective in inhibiting colony formation and proliferation by targeting acidic melanoma cell populations, this disclosing a potential addition to the treatment of advanced melanoma therapy [227]. Finally, another biguanide, like phenformin, has also been ascribed to have an anticancer effect via mechanisms involving disruption of MCTs [221].

9.8. Perillyl alcohol (POH)

The monoterpene perillyl alcohol (POH) is isolated from the essential oils of several plants. It shows anti-cancer effects presumably related to its Na^+/K^+ -ATPase inhibitory properties as well as to its activity as an intracellular acidifier, similar to cardiac glycosides [228,229]. POH has been used in the treatment of several malignant tumors, including gliomas [230]. It also induces growth arrest and apoptosis of leukemia cells [231]. There are occasional but impressive reports of complete remissions of recurrent glioblastoma treated with POH via intranasal administration [232]. Also, POH administrated via inhalation, concomitantly with oral temozolomide, has been reported to halt the progression of recurrent glioblastoma [233].

9.9. 3-Bromopyruvate (3BP)

A certain success in treating advanced cancers with 3BP has already been demonstrated in the clinical setting [234,235]. Multiple reports indicate that the small molecule “energy blocker” 3BP transport into cancer cells is mediated by H^+ -coupled or Na^+ -coupled MCTs. MCT1, in particular, is essential to its cytotoxic action [234,236]. Indeed, these studies on the mechanism by which 3BP enters cancer cells suggest that the pH gradient from the extracellular environment to the cell cytoplasm may be crucial since the tumoral extracellular acidic pH increases the affinity for 3BP uptake, an effect possibly due to the up-regulation of MCTs. As a result, this will enhance its selective cytotoxic effect in tumor cells [234,236]. This typical acid-base abnormality of the malignant tumor microenvironment could also explain the lack of secondary effects of 3BP already described in *in vivo* studies. In addition, it has also been shown that 3-BP inhibits glycolysis and mitochondrial respiration inducing cell death in leukemia cells while also acting as a chemosensitizing agent [237].

9.10. Dichloroacetate (DCA)

Dichloroacetate-treated tumor cells show inhibited expression of two key pH regulators: MCT1 and V-ATPase, apart from altering the expression of GLUT1 and HIF-1. DCA shows a tumoricidal effect

on murine T cell lymphoma cells by triggering apoptosis, showing that DCA-dependent alteration of tumor cell survival involves pH homeostasis and glucose metabolism [238]. Different case reports of human malignancies reversed by DCA have been published [239].

9.11. Nigericin

Many other cellular acidifying agents have been studied as anti-cancer agents for at least the last three decades. Among these compounds were: stilbene disulfonates ($\text{Cl}^-/\text{HCO}_3^-$ -exchanger inhibitors), nigericin, DIDS, or the protonophore carbonylcyanide-3-chlorophenylhydrazone (CCCP). Along with amiloride and some of its analogs, nigericin was one of the first intracellular acidifiers studied by the group of Tannock in a series of seminal publications in the field [240–245]. These authors also showed an increased anti-tumoral effect of amiloride when combined with nigericin [240]. More potent amiloride derivatives, such as 5-(N,N-hexamethylen) amiloride (HMA) and ethylisopropyl amiloride (EIPA), together with nigericin, were also reported to consistently inhibit tumor growth [242]. Finally, the cell acidifying role of nigericin can be explained because nigericin is a ionophore that exchanges K^+ for H^+ across most biologic membranes in a similar way than Salinomycin does [246].

9.12. Hyperthermia and radiation and the NHE1-pHi relationship

There has recently been a renewed interest in treating tumors with hyperthermia. Hyperthermia has been reported to decrease pHi [247]. A number of studies show that lowering pHi (almost all by targeting NHE1) can strongly enhance the thermosensitivity of cancer cells [248–252]. Therefore, there are very real possibilities for the combined use of PTIs together with hyperthermia [253]. Furthermore, the combination of hyperthermia and radiation has also been exploited in cancer treatment [254]. Other relationships between pH, radiation and hyperthermia have been reviewed elsewhere [255].

9.13. Docosahexaenoic acid (DHA) and polyunsaturated Omega-3 long-chain fatty acids

The polyunsaturated n-3 fatty acid DHA (docosahexaenoic acid, 22:6n-3) is effective in increasing survival and chemotherapy efficacy in breast cancer patients with metastasis [256], in controlling cancer cell growth [257], in inhibiting the growth of malignant cells [258] and inhibiting survival pathways in cancer cells [259]. The ion channel $\text{NaV}1.5$ has been shown to promote MDA-MB-231 breast cancer cells invasiveness by potentiating the activity of NHE1 [260,261]. DHA inhibits $\text{NaV}1.5$ current and NHE1 activity in human breast cancer cells, and in turn reduces $\text{NaV}1.5$ -dependent cancer cell invasiveness [262]. Similarly, the use of nutritional lipids in the diet, like omega-3 long-chain polyunsaturated fatty acids has been suggested to reduce the invasion of breast cancer cells and to block the development of metastases [263]. This kind of dietary interventions might represent further therapeutic opportunities in association with conventional anti-cancer treatment.

9.14. Cardiac glycosides

By inhibiting Na^+/K^+ -ATPase, cardiac glycosides have been shown to secondarily inhibit NHE1, induce intracellular acidification and, thereby, stimulate apoptosis in cancer therapy [229]. Digoxin and digitoxin have been shown to be anticancer agents at doses used in human cardiologic settings [228,264–267]. Other cardiac glycosides that have shown anti-cancer properties are bufalin, oleandrin and ouabain. Finally, agents like phenytoin, carbamazepine, valproate, lamotrigine, ranolazine, ropivacaine,

lidocaine, mexiletine, flunarizine and riluzole have been recently reviewed and therapeutically repurposed because of their capacity to act as antimetastatic agents after targeting voltage-sodium channels [268].

9.15. Urocanic acid

When an effective amount of urocanic acid is administered, this drug is able to acidify the cytosol causing inhibition of proliferation of both transformed and non-transformed cells. The use of urocanic acid as an enhancer of other therapeutically active agents has also been disclosed [269].

9.16. Photodynamic acidification

Using a photosensitizing agent the pHi of MDA-MB-231 triple negative breast cancer cells (TNBC) drops leading to apoptosis, suppressing tumor growth and increasing survival in mice [270].

10. Ion channels in cancer and neurodegeneration

Some ion channels are significantly involved in both the regulation of pHi/pHe in cancer cells and in the acquisition of proliferative and pro-invasive capacities. Ion channels regulate several cell processes, such as cell proliferation, resistance to apoptosis, cell adhesion, cancer cell motility and extracellular matrix invasion. They also participate in tumor progression through non-excitable functions [271–278]. Consequently, an altered physiology of ion channels has also been proposed as a new hallmark of cancer cells and as a potential target for selective therapeutics [273–281]. On the contrary, cellular acidification resulting from brain ischemia, either preceding or accompanying the clinical manifestations of certain HNDDs in the central nervous system (CNS), has been shown to be dramatically deleterious in provoking neurodegeneration through the participation of pH-sensitive or pH-regulating ion channels [35,37,271,272] (Fig. 3).

10.1. A) Relationships between deregulated tumor pHi/pHe and voltage-gated ion channels in cancer

The homeostasis and allostasis of the pHi/pHe gradient also participates in the control of cellular resting membrane potential (E_m) [282]. This is critical in excitable cells, such as in neurons, since it both triggers and propagates action potentials. In non-excitable cells, membrane hyperpolarization is associated with normal stem cell differentiation and inhibition of mitosis [178]. On the contrary, a depolarized E_m has been identified as an important parameter favoring cancer cell proliferation and migration, and proposed to be essential to maintain cancer stem cells abilities. In this regard, there are several ion channels that are directly gated or their activity modulated by extracellular H^+ including the Acid-sensing Ion Channels (ASIC) [283], the sensory and pain receptor Transient Receptor Potential Vanilloid receptor 1 (TRPV1) [284,285], the Transient Receptor Potential Ankyrin repeat receptor 1 (TRPA1) [286,287], some two-pore domain (K2P) [288], inwardly rectifying K^+ channels (Kir) [289] and the voltage-gated Na^+ , Ca^{2+} and K^+ channels [290]. As a result, a deregulated pH homeostasis will also have dramatic results in either hypo- or hyper-excitability in excitable cells [271] and will also affect cell volume, secretion and proliferation, properties which are also under the dependence of ion channel activity in non-excitable cells, such as in epithelial cells [291].

On the other side, there is a group of voltage-gated H^+ channels (Hv) and their activation results in an outward current, extruding the excess of intracellular H^+ and, therefore, participating in the acidification of the extracellular compartment while affecting membrane potential [292]. Some studies have identified Hv as

being involved in cancer progression. In highly invasive breast cancer cells from the MDA-MB-231 cell line, Hv1 was found to be highly expressed, while it was not, or it does it very weakly, expressed in poorly invasive MCF-7 cells. The down-regulation of Hv1 reduces breast cancer cell migration and invasion in highly metastatic cells and is responsible for inducing intracellular acidification, which indicates a role of Hv1 in the regulation of resting pHi [293]. In another study, the same authors showed that Hv1 expression was significantly correlated with tumor size and clinical stage [294]. Furthermore, the high expression of Hv1 in biopsies was associated with poor prognosis and a shorter recurrence-free and overall survival. *In vitro*, knockdown of Hv1 expression in invasive MDA-MB-231 cells decreases cell proliferation, invasiveness and tumor growth, inhibiting proton secretion, acidification of the extracellular microenvironment and ECM degradation. Hv1 was also found to be strongly expressed in colorectal adenocarcinomas, but not or lowly expressed in normal tissues or in hyperplastic polyps [295]. Also in this kind of tumor, the levels of Hv1 expression correlate with tumor size, lymph node status and clinical stage [295]. Besides, high Hv1 expression is significantly associated with shorter overall and recurrence-free survival, and the inhibition of Hv1 activity in colorectal cancer decreases cell invasion and migration by blocking proton extrusion and intracellular pH recovery [295]. Finally, different inhibitors of the Hv1 voltage-gated proton channels are now being studied as anticancer agents [296].

10.2. B) Relationships between pH, NHE1 and the voltage-gated sodium channels in cancer

Voltage-gated sodium channels (Na_v), carrying inward charges upon gating, are known to be responsible for membrane depolarization and critical for “excitable” cells such as neurons, skeletal and cardiac muscle cells, as well as for the initiation and propagation of action potentials [297,298]. They were initially identified as being characteristic of excitable cells. However, they are also found to be unexpectedly expressed in cancer cells, especially in those of epithelial origins (prostate, breast, lung, colon, cervix and ovary), while they are not expressed in the same non-cancer tissues. This has led to consider them among the new hallmarks of cancer [281]. Their function is associated with cancer progression [277,299,300], metastases and patient death [301,302] (Fig. 3). In highly aggressive human breast cancer cells, the activity of the $Na_v1.5$ isoform was not associated with the triggering of action potentials but it enhanced extracellular matrix (ECM) degradation and cancer cell invasiveness by increasing the activity of the extracellular cysteine cathepsins B and S [300,303] which have maximal activity in acidic conditions [304]. While the mechanistic details by which Na_v promotes cancer cell invasiveness are not fully characterized, it has been demonstrated that invasiveness of malignant cells takes place by persistent $Na_v1.5$ activity (through a persistent window current at the membrane potential). This occurs through the interaction of $Na_v1.5$ with NHE1, which by extruding H^+ and so acidifying the pericellular microenvironment then activates cathepsins [260,303]. Indeed, $Na_v1.5$ activity is responsible for the allosteric modulation of the NHE1, rendering it more active at pHi values between 6.4 and 7. It was suggested that the sodium current was responsible for this regulation [260,261]. Furthermore, NHE1 and $Na_v1.5$ proteins can be co-immunoprecipitated and may physically interact in invadopodia [260,261]. In summary, the activity of Na_v channels in cancer cells has been identified as an important parameter favoring cancer migration through a persistent sodium current that would tend to depolarize the membrane potential of malignant cells [305] while favoring the reversed proton gradient in cancer cells.

From a therapeutic point of view, the use of Na_v -inhibiting drugs has been proposed in order to reduce cancer progression, so increa-




Fig. 3. General scheme showing some shared aspects of the role of altered intracellular pH (pHi) and extracellular pH (pHe) and ion channels in cancer, brain ischemia and HNDDs.

Alterations in both intracellular (pHi) and extracellular (pHe) pH are tightly involved regulating cancer progression and cell death in both brain ischemia and HNDDs (see text for details). In cancer cells, protons (H^+) produced by the glycolytic metabolism are extruded by Na^+/H^+ exchanger (NHE1) and/or other membrane-bound proton transporters and the voltage-gated proton channel, Hv1 [292–296]. The activity of NHE1 is enhanced by voltage-gated sodium channels that are abnormally expressed in cancer cells [260,261,305], as well as by increases in the intracellular Ca^{2+} concentration, which is regulated by the Na^+/Ca^{2+} exchanger (NCX) activity [140] with the participation of numerous Ca^{2+} -permeable channels also up-regulated in cancers [279]. Both the increase in intracellular pH (pHi) and the decrease in extracellular pH (pHe) drive cancer processes such as transformation, proliferation, survival, migration, and ECM proteolysis/invasion. The opposite situation takes place in both ischemia and HNDDs where the low pHi of cells in either condition can be secondary both to an intracellular acidosis of a metabolic origin (metabolic/aerobic acidosis) and/or to acidosis related to a lack of oxygen (hypoxic/anaerobic acidosis). This is associated with the over-activation of acid-sensing ion channels (ASICs), [272,326–329] in ischemia [318–322] and in HNDDs, with glutamate ionotropic receptors (AMPA and NMDA receptors) generating Ca^{2+} overload [310,315–317] and neuronal cell death [36–39,271,342–344]. For further details see text.

Abbreviations: Nav1.5: Voltage-gated sodium channel isoform 1.5; NHE1: Na^+/H^+ exchanger type 1; NCX: Na^+/Ca^{2+} exchanger; ASIC1a: Acid-sensing Ion channel type 1a; Hv1: Voltage-gated proton channel type 1; HNDDs: human neurodegenerative diseases; AMPA-R: (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor); NMDA-R: (N-methyl-D-aspartate receptor); GFRs: Growth Factor Receptors.

seing survival time in patients with cancer [268,277,306,307]. Indeed, inhibitors of Na_v that are clinically used for the treatment of other pathologies, such as ranolazine for the treatment of chronic angina or phenytoin as an anticonvulsant, are powerful pharmacological tools that have been shown to prevent metastatic colonization of organs of immunodepressed mice [308,309]. These studies indicate that inhibitors of Na_v channels, already approved for other clinical uses such as antiarrhythmics, anticonvulsants [302,310] and anaesthetics [311], as well as other compounds [268], can be repurposed for antiinvasive cancer treatment and even for the prevention of metastatic development.

10.3. C) Ca^{2+} homeostasis and NHE1

In glioma cells there is a persistent NHE1 activity consistent with depolarized membrane potentials, calcium loading, high intracellular pH and Na^+ levels. Importantly, while inhibition of NHE1 by cariporide is not toxic to glioma on its own, its combination with the inhibition of the Na^+/Ca^{2+} exchanger NCX1.1 selectively kills

these brain tumor cells [140]. This is consistent with the growing evidence that Ca^{2+} homeostasis is importantly remodeled through the participation of multiple Ca^{2+} channels and transporters. These are expressed at the plasma membrane or in intracellular compartments, participating in enhanced proliferation, cancer cell survival and invasion [279]. A graphic representation of ion channels and their effects on cancer and neural cells is shown in Fig. 3. Changes in intracellular Ca^{2+} concentration, would, in turn, modulate the activity of NHE1, known to be Ca^{2+} -sensitive through the binding of calmodulin to a specific domain of NHE1 [312,313]. Therefore, the activity of numerous Ca^{2+} -permeant ion channels that are deregulated in cancer might also participate in the regulation/deregulation of pHi/pHe and associated cellular functions.

10.4. D) Relationships between pH and ion channels in neurodegeneration

The central nervous system (CNS) demands a tight control of acid-base homeostasis within very narrow limits in order to

properly maintain neuronal excitability, synaptic transmission and neurotransmitter uptake [37,271,272,314]. Changes in pHe, mostly resulting from metabolic stress are deleterious to the CNS and can result in several HNDDs [37,271,272,314]. Indeed, ischemic brain injuries that induce toxic intracellular Ca^{2+} overload produce a deviation towards cellular acidification followed by downstream activation of proteolytic cascades in neurons [315,316] (Fig. 3). This Ca^{2+} overload was initially proposed to be mediated by the excessive release of the neurotransmitter glutamate leading to the over-activation of glutamatergic excitatory NMDA receptors [310,317].

Furthermore, activation of acid-sensing Ca^{2+} -permeable channels expressed during acidosis in peripheral and CNS neurons also modulates network electrical activity and exacerbates neurodegeneration in mice [318]. Spontaneous neurotransmitter release was reduced by ASIC1a activation at motor nerve terminals and these effects were emulated by acid solutions [319]. In this respect, it has been hypothesized that the intracellular H^+ concentration, acting as a second messenger or via modulation of ion channel activity governs neuronal excitability [320]. This lowering of CNS pH stimulates the opening of ASIC1 channels and a cellular entry of Ca^{2+} , which further damages many cellular functions and even provokes neural cell death (Fig. 3) [321]. In amyotrophic lateral sclerosis (ALS), intracellular acidification-mediated apoptosis is involved in the Ca^{2+} -dependent glutamate mediated neural cell death that is considered to be responsible for disease progression [321,322].

The hypoxic tumoral microenvironment is quite similar to what happens during brain ischemic hypoxia or strokes and, apparently, also in certain HNDDs (Fig. 3). In these situations, oxygen depletion forces brain cells to use anaerobic glycolysis for the production of ATP, which induces the accumulation of lactic acid and H^+ in the extracellular compartment and causes pHe acidification to values between 6.0 and 6.5 [323]. These low pHe conditions further aggravate ischemic brain damage, neuronal injury and glial cell death [296,324,325]. Importantly, cell death induced by acidosis was inhibited by ASIC blockers and cells lacking endogenous ASICs were resistant to acid injury [272]. This pHe-driven and ASIC-dependent mechanism was further demonstrated *in vivo* in focal ischemia, for which the intracerebroventricular injection of ASIC1a blockers, or knocking-out the expression of the ASIC1a gene, protected the brain from ischemic injuries [326]. Multiple studies have supported the participation of homomeric ASIC1a channels, as well as of heteromeric channels composed of ASIC1a and ASIC2b [327] in acid-mediated neurotoxicity. Recently, it was demonstrated in CA1 hippocampal neurons, which are highly vulnerable to ischemic stroke, that ASIC1a activation under extracellular acidosis contributes to post-ischemic glutamatergic Ca^{2+} -permeable AMPA receptor plasticity. This identifies a functional interaction between acidotoxicity and excitotoxicity and suggests that ASIC1a and Ca^{2+} -permeable AMPA receptors are potential drug targets for neuroprotection [328]. In addition to ischemic stroke, ASICs have now been implicated in many other pathologies in the CNS, such as multiple sclerosis, Huntington's disease, Parkinson's disease and spinal cord injury (for a review, see ref [329]). Thus, the pharmacological targeting of ion channels such as ASICs [261,276,326], glutamatergic Ca^{2+} -permeable receptors and/or even Na^+ channels [307] could represent new strategies for the treatment of either malignant disease and in the prevention and treatment of post-ischemic and neurodegenerative pathologies. In summary, there is an increasing amount of evidence that pH-linked ion channels pathophysiology present a potential therapeutic effect both in human cancer and in improving understanding of HNDDs pathogenetic mechanisms as well as leading the way towards novel and cutting-edge forms of treatment in both situations.

11. Cell death and neuroprotection in HNDDs. A transversal extension from the pH-centric translational cancer paradigm to the etiopathogenesis and therapeutics of neurodegeneration

11.1. The pH-centric cancer paradigm in HNDDs. Is the intracellular pH a key homeostatic factor for understanding and treating human neurodegenerative diseases?

The pH-centric paradigm can be applied to HNDDs in order to improve our understanding of the nature of the abnormalities underlying the pathological deregulation of neural cell death and/or malfunctioning [330–334]. In this context, a pH-related approach helps to clarify many of these two metabolically and biochemically opposed situations: cancer and neurodegeneration. This new approach is based upon the fact that, regarding cellular acid-base homeostasis, cancer and HNDDs, such as Alzheimer's disease (AD) and other HNDDs can be looked at as two situations at both opposite ends of the metabolic spectrum (Table 3) [35–39,331,334,335]. This perspective also leads to a new integral paradigm pointing towards a unified theory of the apoptosis-antiapoptosis machinery and/or the cellular programmed pro-death/anti-death mechanisms. It will also help to understand the scientific reason behind the fact that in epidemiological studies AD and cancer show an inverse association among them [336].

In order to better understand these dynamics it is necessary to take into account the effects of acid-base disturbances on neuronal functions and what is known about the role of acid-base regulatory mechanisms in blocking the lowering of neuronal pH under physiopathological conditions, a subject that has been increasingly considered over the years [37,38,271,272,314,330,333,335,337–340]. Intracellular acidification has been found to be more pronounced in the brains of AD patients [272,335] and β -amyloid aggregation in AD is induced by acidosis and is reverted upon microenvironmental alkalization [341]. Most importantly, while acidification provokes neural cell death, pH alkalization shows beneficial effects on the evolution of ALS in mice [307,321,335,341]. Seminal work in this area [39] showed that lowering pH of neurons from 7.36 to 7.09/7.00 through exposure to nitric oxide (NO) sets in motion a programmed cell death program, increasing DNA fragmentation and decreasing neuronal survival ("low pH-mediated metabolic collapse"). Indeed, intracellular acidification determines apoptosis and other related cell death programs and mechanisms [36,37,271,342,343]. In neuronal injury this apoptotic phenomenon is induced by the activation of three low pH-dependent endonucleases [39,344]. Thus, the importance of maintaining a strict and narrow range of pH/pHe homeostasis in the CNS neural cell protection becomes evident since it controls neuronal hyper- and hypo-excitability, synaptic transmission, neurotransmitter uptake, intercellular communication, nociception and inflammation. Indeed, the cellular death that spontaneously takes place in HNDDs like AD [345] seems to represent the same phenomenon that occurs in cancer therapeutics designed to selectively induce pro-apoptotic acidification that aim to lower pH below survival levels through a wide array of different approaches and methods as discussed above (Tables 1 and 3).

Recent studies in an *in vitro* model of excitotoxic neuronal death reported that the potent NHE1 inhibitor cariporide, perhaps paradoxically at first sight, protected neurons from ischemic injury and this effect was ascribed to the prevention of CNS apoptosis. In that study, cariporide (100 nM) was found to reduce both glutamate-induced necrotic and apoptotic neuronal cell death. Cariporide attenuated glutamate-mediated mitochondrial death pathways involving loss of mitochondrial membrane potential as well as Ca^{2+} and reactive oxygen species (ROS) accumulation [346].

These results further suggest that, at least indirectly, NHE1 participates in the necrotic cell death process and that its inhibition offers a means of preventing both necrosis and apoptosis. In the same vein, PPIs seem to increase the risk of dementia, probably through a pH effect [347].

Also the more general NHE inhibitor, amiloride, has been shown to have protective effects in different neurodegenerative situations by preventing acidosis-induced cation overload and preserving myelin levels in hypoxic and inflammatory conditions [348]. These results further suggest that, at least indirectly, NHE1 participates in the necrotic cell death process and that its inhibition offers a means of preventing both necrosis and apoptosis. Among the different proton transporters, NHE1 appears to be the main mechanism that drives neural cells to a pathological decrease in pH_i and, therefore, towards cellular death through cytosolic acidification [37,349]. That is, blocking NHE1 activation with cariporide may provide neuroprotection following brain hypoxia by protecting cells from Ca²⁺ entry and ROS [350]. Interestingly, it has also been shown that the patients' lymphoblasts mirror that which takes place in the nervous tissue in terms of NHE1 activity and pH regulation, suggesting that this might serve as a potential non-invasive test of the response of neural disease to different therapies [314]. Namely, treatments that best return lymphoblast pH towards physiological values should do the same to the nervous tissue [314].

Finally, while the genetic conditioning and background of the pH/NHE system has been considered in the field of oncology [33,193], we are not aware that these relationships have been ever considered in HNDDs in spite of multiple studies following different research lines in the study of the genetics of HNDDs [351–353].

12. Growth factors and melatonin in HNDDs and cancer. Lack of trophic factors leads to decreased trophism and mobility

12.1. A) Deficiencies of human Growth Factors (hGFs) and other hormone deficiencies in HNDDs

In many cell types, including those of the hematopoietic system, removal of essential growth factors results in apoptosis [354]. The general concept behind this perspective is very simple: HNDDs have been shown to lack of different trophic and/or growth factors, and a general characteristic of HNDDs is “lack of trophism and/or mobility” [35]. Thus, the most rational therapeutic approach would be to provide the missing trophic factors and/or to stimulate the deficient systems involved. Perhaps, a certain unawareness of this feature is behind the overall failure in the treatment of HNDDs and many other degenerative processes, from joint degeneration in chronic arthritis to peripheral nerves neurodegeneration [36,37,355]. The problem is to know why and how the lack of certain hGFs leading to neurodegeneration appears, and whether a decrease of neural and/or non-neural hGFs factors is directly responsible for the different neurodegenerative processes. In this line, there is evidence from animal and human studies that link cognitive deficits with changes in brain and peripheral trophic factors, while exercise, by increasing the levels of IGF-1 and other neural and non-neural in origin growth factors, induce cognitive improvements in different HNDDs [356].

An important aspect of this concept is that NHE1 activity is known to be a fundamental mechanism in the pH_i regulation in the CNS [349]. It has also been known for a long time that different growth factors, platelet-derived (PDGF) or otherwise, activate NHE [123,357]. This increases intracellular pH_i and stimulates cellular metabolism and DNA synthesis [358]. From these pathogenetic associations a direct therapeutic consequence is easy to recognize

now [98,123,359] possibly leading to the right approach to the treatment of at least some HNDDs (Fig. 1) [35,36].

12.2. B) Human growth hormone (hGH) and melatonin (MT) in HNDDs and cancer. A beneficial side-effect of the new therapeutic trends?

12.2.1. I – hGH in HNDDs

Ageing is related to the progressive lack of a number of neurotrophic factors, including human growth hormone (hGH) among them, this decay being considered a physiological process [360]. For decades, hGH administration in elderly people has been reported to improve cognition and metabolic alterations typical of old age [361]. The effects of hGH on cognition have been widely documented, particularly on learning and memory [362,363]. Moreover, a recent study in injured rats demonstrated that hGH treatment had a positive effect on cognitive function, most likely by increasing expression of hippocampal and prefrontal Brain Derived Nerve Factor (BDNF) and Tyrosinkinase B (TrkB) [364]. hGH and its receptor (GHR) are produced in neural stem cells in all animal species studied and this local production leads neural stem cells to proliferate, differentiate, migrate and survive. For these effects Pi3 K/Akt and ERK 1/2 play a key role [321]. In rats, growth hormone (GH) administration cooperates with locally-produced GH (non human growth hormone) in brain repair after an injury and peripheral GH induces neural cell proliferation in the intact adult rat brain. However, the last upstream factor responsible for cellular survival is the activation of jun n-terminal kinase (JNK) [365]. Indeed, exogenous hGH administration cooperates with locally-produced hormone in increasing the proliferative response of hippocampal progenitors to an injury [366]. Moreover, hGH may facilitate brain plasticity and early hGH treatment promotes relevant motor functional improvement after severe frontal cortex lesions in adult rats [367].

Importantly, hGH also induces the expression of a number of neurotrophic factors (IGF-I, EGF and its receptor, EPO, VEGF, NGF) (Fig. 1) and increases the cerebral metabolic turnover of NA (Noradrenaline) and DA (Dopamine) [360,367–372]. While it is known that neural progenitors are produced at the cerebral level in different neurogenic niches along the whole life, their production also progressively decreases as the subject ages. It remains to be established whether the effect of hGH administration might compensate this physiological age-related decrease production and/output of different human growth factors (HGF), neural-derived or otherwise, but preliminary results from our group indicate that this occurs [373]. While the neurotrophic effect of hGH, either exerted by itself or by inducing the expression of a number of neurotrophic factors is now clear (Fig. 1), no long ago it seemed that this effect was exerted only after a traumatic brain injury (TBI) or after a stroke or in children with cerebral palsy, when suffering GH-deficiency as a result of the brain insult. However, the positive effects played by GH on brain repair after an injury have been also demonstrated in TBI patients without GH-deficiency [374,375]. In spite that hGH concentrations are low in the cerebrospinal fluid of patients with Amyotrophic Lateral Sclerosis (ALS), a clinical trial demonstrated that hGH administration exerted no effect in the clinical progression of this fatal neurodegenerative disease [375,376]. However, studies *in vitro* and in animal models of ALS demonstrated that GH administration played a protective effect on mutant SOD-1-expressing motor neurons, increasing the survival time and improving motor performance and weight loss of GH-treated transgenic mice [377]. On the other hand, it has been shown that in animal models the intra-hippocampal injection of the hormone improves spatial cognition [378] as well as learning and memory in AD-like rats [379]. Therefore, a possible usefulness of hGH in AD has been recently postulated [380]. It is possible that the time at which hGH administration is given in relation to the development

of AD may play a significant role in the results obtained. In fact, GH has been shown to prevent age-induced reduction in the expression of some components in rats, including cytochromes b and c of the mitochondrial respiratory chain [381,382].

12.2.2. II–Melatonin (MT) in HNDDs

Cell death and survival are known to be critical events for the evolution of neurodegeneration [35], while mitochondria being increasingly seen as an important determinant of both processes. Indeed, mitochondrial dysfunction is considered to be a major etiopathogenic factor in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) [383]. The mechanisms thought to be involved in impaired mitochondrial function include increased free radical generation, enhanced mitochondrial inducible NO synthase activity and NO production, pH changes, a disrupted electron transport system and mitochondrial permeability transition [39,383,384]. Furthermore, the CNS is very sensitive to oxidative stress, which is considered to be a key factor in the pathophysiology of neurodegenerative disorders.

Melatonin (MT) has been shown to be effective in preventing the oxidative stress/NO stress-induced mitochondrial dysfunction seen in experimental models of AD, PD and HD [383]. This hormone has unique biochemical properties such as scavenging of hydroxyl, carbonate, alkoxyl, peroxy and aryl cation radicals and stimulation of the activities of important antioxidative enzymes like glutathione peroxidase and superoxide dismutase and can suppress nitric oxide synthase. For all these reasons it may have an important role in the treatment of HNDDs [384].

Therefore, recent studies have considered the potential clinical role of MT in the main HNDDs like AD, PD, ALS and multiple sclerosis (MS). In mouse models of AD, a significant clinical improvement with chronic MT treatment at daily dosages of 10 mgr/kg/day was obtained [385], with improvement of cognition and memory and reduction of the deposits of A β [386]. Most recent data on ALS patients indicate that high doses of MT can be useful in delaying the progression of this fatal disease. Importantly, MT also appears to be most beneficial in other neurovascular diseases like the highly invalidating Horton's disease ("cluster headaches") when used in high pharmacological doses, from 50 to 350 mgr/day, or even higher dosages, similar to how it has been used in patients with ALS [387,388]. Similar beneficial effects have been recently described in an animal model of sporadic AD (OXYS rats). In this situation, early treatment with MT induces a decrease of amyloid- β 1-42 and amyloid- β 1-40 levels in the hippocampus and of amyloid- β 1-42 levels in the frontal cortex [389]. In addition, treatment of OXYS rats with this hormone slowed down the increase in anxiety and deterioration of reference memory typical of AD [389]. These properties make this hormone unique for protecting the organism against the oxidative stress by inducing a reduction in the oxidative damage which, as above described, is considered as a key factor in the etiopathogenesis of HNDDs [383,390]. In summary, MT administration at pharmacological dosages should be considered a promising adjuvant treatment of certain HNDDs.

12.2.3. III – Melatonin (MT) as an oncostatic and cytotoxic agent

It is known that MT is produced not only at the pineal level but in all the cells of any living organism, vegetables and unicellular organisms included, where it plays a key role in maintaining normal cellular homeostasis, most likely by regulating cell oxidative metabolism [391,392]. Some effects of MT on cellular homeostasis also seem to be strong in cancer cells showing a metabolic profile consistent with aerobic glycolysis (Warburg effect, increased glucose uptake, LDH activity, lactate production and HIF-1 α activation). Here, MT is able to revert this metabolic profile inducing cytotoxicity, while in cancer cells where the Warburg effect is not

seen it inhibits proliferation [393]. Finally, the differential regulation of metabolism by MT could also explain why the hormone is harmless for a wide spectrum of normal cells and a minority of malignant cells while it kills specific tumor cell types [394,395].

These effects of MT on cancer could be surprising since the hormone has been considered for some time as a simple synchronizer between the organism and the environment. MT also behaves as an oncostatic agent [396]. At both physiological and pharmacological doses, MT has been shown to be effective in suppressing neoplastic growth in a variety of tumors like melanoma, breast, prostate, ovarian and colorectal cancer [393,397,398]. It seems that this effect is mediated by the direct augmentation of natural killer (NK) cell activity as well as the stimulation of cytokine production, for example, interleukins IL-2, IL-6, IL-12 and interferon (IFN)-gamma [397]. The same authors have suggested that the physiological surge of MT at night could be considered a "natural restraint" on tumor initiation, promotion and progression, and it has been recently advanced that disrupting circadian nocturnal melatonin rhythms promotes human breast cancer growth and resistance to chemotherapy [393]. It is therefore logical that MT is increasingly becoming an adjuvant therapy in some human malignancies, even preventing adverse side-effects produced by chemo/radiotherapy such as mucositis [399]. In summary, MT appears not only to be a protecting agent against the development of certain HNDDs but also seems to be beneficial in counteracting the progression of a number of malignant tumors. However, further clinical experience in this new area is necessary.

12.3. C) Neural and platelet-derived human growth factors (PDGFs) in the treatment of HNDDs

These new approaches clearly open the possibility of using different human growth factors (hGFs) for neuronal protection in HNDDs, either derived from hGFs stimulation, also induced by hGH [373,374] or derived from platelet concentrates (Fig. 1). This was initially suggested by our group within the frame of a new concept that was called "the trophic factor withdrawal syndrome" (TFWS) [35,36]. In this vein, it has been recently shown that intranasal delivery of platelet-derived plasma rich in growth factors (PRGF) enhances hippocampal neurogenesis and reduces neurodegeneration in an amyloid precursor protein/presenilin-1 (APP/PS1) mouse model of AD [400]. PRGF also reduces neuropathologic hallmarks and improves cognitive functions in the AD mouse model [401]. In a parallel study, these authors have shown that hGFs from PRGF preparations induce neuroprotection in rodent models of Parkinson's disease (PD) by modulating pro-inflammatory processes. In that study, the effects of PRGF as a therapeutic approach to PD were evaluated in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse and these effects were associated with a significant reduction in nuclear transcription factor- κ B (NF- κ B) activation and nitric oxide (NO), cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF- α) expression in the substantia nigra [402]. From these studies, it can be concluded that PRGF can prevent dopaminergic degeneration via an NF- κ B-dependent signaling process. However, in spite that some relationships between platelet-derived growth factors (PDGFs), NO production and the acid-base cellular changes in HNDDs under these therapeutic measures have been described, they are still waiting to be fully understood [35,39,344]. At the present time it is not known if the results of these experiments are always mediated by the stimulating effect of PRGF and/or hGH on maintaining cellular acid-base homeostasis within physiological limits, so preventing the metabolic collapse induced by cell acidification and subsequent cellular death through apoptosis or similar mechanisms (Table 1). However, some evidence seems to indicate

that this can be a fundamental mechanism in preventing and/or controlling neurodegeneration (Fig. 1 and Table 3) [35,37,38].

Finally, in spite that the possibility of stimulating tumor growth with the utilization of hGH and/or hGFs and PDGFs has been raised [36,403–406], the extensive clinical experience already available using PRGFs in many different areas of regenerative medicine appears not to have not shown any oncogenic danger [407].

13. Conclusions

- a Historically, systemic acid-base balance was recognized by classic medicine as the fundamental parameter to define the general concept of homeostasis. More than a century later this concept can now be extended to the cellular level where the pH and hydrogen ion dynamics occurring in cancer and neurodegeneration are seen as deviations towards opposite ends of a biological and metabolic spectrum. Also, and for the first time, both the metabolism of cancer and HNDDs can be viewed under the same wide-ranged perspective at different levels of understanding, from both basic and clinical aspects and from etiopathogenesis to treatment.
- b The pH-centric paradigm of cancer developed in this contribution permits a deep understanding of the many faces and stages of malignant disease, from cell transformation to local growth, dissemination and the metastatic process, as a single, integrated process driven by altered acid-base regulation at different phases of evolution and development.
- c Regarding cancer etiopathogenesis and treatment, the primary aim of this H⁺ ion dynamics-based approach (“the pH-centric paradigm”) is to manipulate the dysregulated pH abnormal dynamics of cancer cells and tissues in order to reverse tumor growth, control local invasion and deactivate the metastatic process. These abnormal cellular pH-dynamics of cancer and its consequences can be considered a chronic allostatic failure in maintaining cellular acid-base homeostasis within physiological parameters.
- d The main therapeutic aim of the pH-centric paradigm in translational and bedside oncology is the induction of a proapoptotic selective intracellular acidification of cancer cells using different membrane-bound inhibitors of proton transport and of other non-proton transport derived cellular acidifiers. This would reverse the selective cancer proton reversal of malignant cells and tissues and consequently increase tumoral interstitial pH. At the same time, this would inhibit the Warburg effect and act as an antglycolytic measure, thus controlling cancer growth and the metastatic process. This perspective represents a rational approach to cancer therapeutics encompassing all stages of cancer development at the same time and it has the potential of being selectively exploited in the treatment of many, if not all, malignant solid tumors and leukemias.
- e Since cancer cells use different proton pumps and transporters to protect themselves from an intracellular accumulation of hydrogen ions, it is probable that an integrated and concerted utilization of all known inhibitors of proton extrusion in pharmacological dosages will be necessary in the therapy of human malignancies. This is due to the fact that there are multiple pH regulators at the membrane of cancer cells that can be co-expressed at the same time in hostile conditions and also that the inhibition of one transporter will be compensated by the overactivation of other/s (“the neostrategy of cancer cells and tissues”).
- f For the first time, the basic to clinical approach within the field of oncology research advanced here (*translational research*) is now enriched by an interdisciplinary effort to stimulate a more outreaching vision in order to integrate within the same theoretical frame an otherwise separated area of research like

neurology (*transversal research*). This wide-ranged perspective of the entire pH-related cellular homeostasis field and metabolic spectrum offers the opportunity to significantly improve the understanding of the contradictory nature of the acid-base and energetic abnormalities underlying the pathological deregulation of cell death in these two specular processes. In this context, an intracellular pH (pHi)-related approach to these two metabolically opposed situations like cancer and human neurodegenerative diseases (HNDDs) provides a new integral model and new paradigm pointing towards a general and unified theory of the apoptosis-antiapoptosis dualistic machineries and/or cellular programmed pro-death and anti-death mechanisms.

- g One of the main aims of this contribution is to promote the new pH-centric paradigm on the therapeutic utilization of proton transport inhibitors and other non proton transport-derived intracellular acidifiers as well as drugs affecting ion channels physiopathology in human cancer.
- h Finally, we advance that the utilization of a wide array of human growth factors (hGFs) and hormones like human growth hormone (hGH) and melatonin (MT), may have an important role in the oncoming treatments of HNDDs like Alzheimer disease and that those therapeutic measures seem to be able to reverse the acidification-dependent neural toxicity and apoptosis characteristic of neurodegeneration by stimulating cellular metabolism and defending its homeostasis through the therapeutic activation of NHE1 and other membrane-bound proton transporters.

Conflicts of interest

The authors declare the following competing financial interests: EA is the Scientific Director and GO is a scientist at the BTI-Biotechnology Institute, a dental implant company that performs research in the fields of oral implantology and PRGF-Endoret technology. The rest of the authors declare no conflicts of interest.

Funding

This work was supported by the Mercedes Castresana Foundation, Vitoria, Spain (SH) and the Association for Proton Cancer Research and Treatment (APCRT), Madrid, Spain (SH, DPO). CR was supported by the BBSRC UK and University of Nottingham UK; SR by the “Ministère de la Recherche et des Technologies”, the Inserm, the “Ligue Nationale Contre le Cancer”, the Région Centre (grant “NaVMetarget”), the project “ARD2020 Biodrugs” and the “Association CANCEN”.

Acknowledgments

The authors wish to acknowledge the collaboration of Dr. Dario Acuña-Castroviejo and Dr. Patrick Williamson for useful advice. Finally, we wish to thank of Ms. Virginia Cuadrado, Ms. Lorea Sánchez and Mr. Iñigo Ruiz, of The Biotechnology Institute (BTI), Vitoria, Spain, for their significant and generous collaboration.

Finally, the authors wish to apologize to all investigators who have contributed to the different research fields studied in this contribution, past and present, but whose work is not specifically cited in this contribution.

References

- [1] B. Halpern, Concepts philosophiques de Claude Bernard d'après l'Introduction à l'étude de la Médecine expérimentale. Revue d'histoire des sciences et de leurs applications. (1966), 97–114.
- [2] F.L. Holmes, Claude Bernard, the milieu interieur, and regulatory physiology, *Hist. Philos. Life Sci.* 8 (1986) 3–25.
- [3] W.B. Cannon, Organization for physiological homeostasis, *Physiol. Rev.* 9 (1929) 399–431.

- [4] H. Selye, The evolution of the stress concept, *Am. Sci.* 61 (1973) 692–699.
- [5] Allostasis, Homeostasis, and the Costs of Physiological Adaptation, in: J. Schulkin (Ed.), Cambridge University Press, Cambridge UK, 2004.
- [6] U. Halbreich, Allostasis, homeostasis and the cost of physiological adaptation, *Am. J. Hum. Biol.* 17 (2005) 821–822.
- [7] S. Harguindey, M. Katin, F. Edgerton, H. Takita, Hierarchical organization, integrations in biology and cancer, balance loss, and a question on modernism, *Med. Hypotheses* 7 (1981) 1123–1132.
- [8] S. Harguindey, W. Speir, R. Kolbeck, E. Bransome, Alkalotic disequilibrium in patients with solid tumors: rediscovery of an old finding, *Eur. J. Cancer* 13 (1977) 793–800.
- [9] S. Harguindey, J.L. Arranz, J.D. Polo Orozco, C. Rauch, S. Fais, R.A. Cardone, et al., Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs—an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research, *J. Transl. Med.* 11 (2013) 282.
- [10] V. Huber, A. De Milito, S. Harguindey, S.J. Reshkin, M.L. Wahl, C. Rauch, et al., Proton dynamics in cancer, *J. Transl. Med.* 8 (2010) 57.
- [11] B.A. Webb, M. Chimenti, M.P. Jacobson, D.L. Barber, Dysregulated pH: a perfect storm for cancer progression, *Nat. Rev. Cancer* 11 (2011) 671–677.
- [12] D. Neri, C.T. Supuran, Interfering with pH regulation in tumours as a therapeutic strategy, *Nat. Rev. Drug Discov.* 10 (2011) 767–777.
- [13] E.P. Spugnini, P. Sonveaux, C. Stock, M. Perez-Sayans, A. De Milito, S. Avnet, et al., Proton channels and exchangers in cancer, *Biochim. Biophys. Acta* 1848 (2015) 2715–2726.
- [14] N. Baldini, P. Sonveaux, A. De Milito, C.T. Supuran, A.M. Otto, C.M. Stock, et al., Metabolism and microenvironment in cancer plasticity. Meeting report of the 2nd meeting of the International Society of Cancer Metabolism *Cancer & Metabolism* (2016) 4:1.
- [15] S. Harguindey, Integrating fields of cancer research through pivotal mechanisms and synthetic final pathways: a unifying and creative overview, *Med. Hypotheses* 58 (2002) 444–452.
- [16] P. Swietach, R.D. Vaughan-Jones, A.L. Harris, A. Hulikova, The chemistry, physiology and pathology of pH in cancer, *Philos. Trans. R Soc. Lond. B Biol. Sci.* 369 (2014) 20130099.
- [17] S. Harguindey, The unitary strategy of cancer cells: the hydrogen ion as a multidimensional unitary factor and carbohydrate metabolism (second of three parts), *Anales de medicina interna (Madrid, Spain)* 11(6). 1994; 11: 299–303.
- [18] S. Harguindey, G. Orive, J. Luis Pedraz, A. Paradiso, S.J. Reshkin, The role of pH dynamics and the Na⁺/H⁺ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin—one single nature, *Biochim. Biophys. Acta* 1756 (2005) 1–24.
- [19] S.J. Reshkin, R.A. Cardone, S. Harguindey, Na⁺-H⁺ exchanger, pH regulation and cancer, *Recent Pat. Anticancer Drug Discov.* 8 (2013) 85–99.
- [20] S. Harguindey, E.J. Cragoe Jr., The Na⁺/H⁺ antiporter in oncology in the light of the spontaneous regression of cancer and cell metabolism, *Med. Hypotheses* 39 (1992) 229–237.
- [21] M.V. Shirmanova, I.N. Druzhkova, M.M. Lukina, M.E. Matlashov, V.V. Belousov, L.B. Snopova, et al., Intracellular pH imaging in cancer cells in vitro and tumors in vivo using the new genetically encoded sensor SypHer2, *Biochim. Biophys. Acta* 1850 (2015) 1905–1911.
- [22] S. Fais, Evidence-based support for the use of proton pump inhibitors in cancer therapy, *J. Transl. Med.* 13 (2015) 368.
- [23] M. Yu, C. Lee, M. Wang, I.F. Tannock, Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors, *Cancer Sci.* 106 (2015) 1438–1447.
- [24] S. Fais, A nonmainstream approach against cancer, *J. Enzyme Inhib. Med. Chem.* (2016) 1–8.
- [25] R. Falcone, M. Roberto, C. D'Antonio, A. Romiti, C.E. Milano, C.E. Onesti, et al., High-doses of proton pumps inhibitors in refractory gastro-intestinal cancer: a case series and the state of art, *Dig. Liver Dis.* (2016), <http://dx.doi.org/10.1016/j.dld.2016.08.126>.
- [26] P. Marchetti, A. Milano, C. D'Antonio, A. Romiti, R. Falcone, M. Roberto, et al., Association between proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumors: a randomized phase II trial, *Clin. Colorectal Cancer* (2016), <http://dx.doi.org/10.1016/j.clcc.2016.06.005>.
- [27] J. Sun, A.I. Ilich, C.A. Kim, M.P. Chu, G.G. Wong, S. Ghosh, et al., Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients, *Clin. Colorectal Cancer* 15 (2016) 257–263.
- [28] A. Ibrahim-Hashim, J.W. Wojtkowiak, M. de Lourdes Coelho Ribeiro, V. Estrella, K.M. Bailey, H.H. Cornnell, et al., Free base lysine increases survival and reduces metastasis in prostate cancer model, *J. Cancer Sci. Ther. (Suppl 1 (4))* (2011), JCST-S1-004.
- [29] A. Ibrahim Hashim, H.H. Cornnell, L. Coelho Ribeiro Mde, D. Abrahams, J. Cunningham, M. Lloyd, et al., Reduction of metastasis using a non-volatile buffer, *Clin. Exp. Metastasis* 28 (2011) 841–849.
- [30] S. Harguindey, J.L. Arranz, M.L. Wahl, G. Orive, S.J. Reshkin, Proton transport inhibitors as potentially selective anticancer drugs, *Anticancer Res.* 29 (2009) 2127–2136.
- [31] H. Nagata, X.F. Che, K. Miyazawa, A. Tomoda, M. Konishi, H. Ubukata, et al., Rapid decrease of intracellular pH associated with inhibition of Na⁺/H⁺ exchanger precedes apoptotic events in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxazine-3-one, *Oncol. Rep.* 25 (2011) 341–346.
- [32] C. Xiao-Fang, C.-L. Zheng, S.-I. Akiyama, A. Tomoda, 2-Aminophenoxazine-3-one and 2-amino-4, 4α-dihydro-4α, 7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells, *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 87 (2011) 199.
- [33] I.N. Rich, D. Worthington-White, O.A. Garden, P. Musk, Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na⁺/H⁺ exchanger, *Blood* 95 (2000) 1427–1434.
- [34] M.F. McCarty, J. Whitaker, Manipulating tumor acidification as a cancer treatment strategy, *Altern. Med. Rev.* 15 (2010) 264–272.
- [35] S. Harguindey, G. Orive, R. Cabellos, E.M. Hevia, R.D. de Otazu, J.L. Arranz, et al., An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS), *Neuropsychiatr. Dis. Treat.* 4 (2008) 1073–1084.
- [36] S. Harguindey, S.J. Reshkin, G. Orive, J.L. Arranz, E. Anitua, Growth and trophic factors, pH and the Na⁺/H⁺ exchanger in Alzheimer's disease, other neurodegenerative diseases and cancer: new therapeutic possibilities and potential dangers, *Curr. Alzheimer Res.* 4 (2007) 53–65.
- [37] B. Fang, D. Wang, M. Huang, G. Yu, H. Li, Hypothesis on the relationship between the change in intracellular pH and incidence of sporadic Alzheimer's disease or vascular dementia, *Int. J. Neurosci.* 120 (2010) 591–595.
- [38] D. Ding, S.I. Moskowitz, R. Li, S.B. Lee, M. Esteban, K. Tomaselli, et al., Acidosis induces necrosis and apoptosis of cultured hippocampal neurons, *Exp. Neurol.* 162 (2000) 1–12.
- [39] A.M. Vincent, M. TenBroeke, K. Maiese, Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death, *J. Neurobiol.* 40 (1999) 171–184.
- [40] L.E. Gerweck, K. Seetharaman, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, *Cancer Res.* 56 (1996) 1194–1198.
- [41] S.J. Reshkin, A. Bellizzi, S. Caldeira, V. Albarani, I. Malanchi, M. Poignee, et al., Na⁺/H⁺ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes, *FASEB J.* 14 (2000) 2185–2197.
- [42] R. Schammim, S.R. Amith, S. Fong, S. Baksh, L. Fliegel, Na⁺ (+)/H⁺ exchange in the tumour microenvironment: does NHE1 drive breast cancer carcinogenesis, *Int. J. Dev. Biol.* 59 (2015) 367–377.
- [43] S.J. Reshkin, M.R. Greco, R.A. Cardone, Role of pH_i and proton transporters in oncogene-driven neoplastic transformation, *Philos. Trans. R Soc. Lond. B Biol. Sci.* 369 (2014) 20130100.
- [44] R. Perona, F. Portillo, F. Giraldez, R. Serrano, Transformation and pH homeostasis of fibroblasts expressing yeast H⁺-ATPase containing site-directed mutations, *Mol. Cell. Biol.* 10 (1990) 4110–4115.
- [45] C. Wigerup, S. Pahlman, D. Bexell, Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer, *Pharmacol. Ther.* 164 (2016) 152–169.
- [46] C. Pinheiro, A. Longatto-Filho, S.M. Pereira, D. Elinger, M.A. Moreira, L.F. Jube, et al., Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma, *Dis. Markers* 26 (2009) 97–103.
- [47] V. Miranda-Gonçalves, S. Granja, O. Martinho, M. Honavar, M. Pojo, B.M. Costa, et al., Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas, *Oncotarget* 7 (2016) 46335–46353.
- [48] S.F. Martins, R. Amorim, M. Viana-Pereira, C. Pinheiro, R.F.A. Costa, P. Silva, et al., Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis, *BMC Cancer* 16 (2016) 535.
- [49] S.J. van Kuijk, A. Yaromina, R. Houben, R. Niemans, P. Lambin, L.J. Dubois, Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis, *Front. Oncol.* 6 (2016) 69.
- [50] S. Ferro, J. Azevedo-Silva, M. Casal, M. Côte-Real, F. Baltazar, A. Preto, Characterization of acetate transport in colorectal cancer cells and potential therapeutic implications, *Oncotarget* (2016).
- [51] L. Counillon, Y. Bouret, I. Marchiq, J. Pouyssegur, Na⁺/H⁺ antiporter (NHE1) and lactate/H⁺ symporters (MCTs) in pH homeostasis and cancer metabolism, *BBA—Mol Cell Res.* 1863 (2016) 2465–2480.
- [52] C. Rauch, B.A. W. ED, L. Miriam, H.S. Wahl, Cell Membranes, Cytosolic pH and Drug Transport in Cancer and MDR: Physics, Biochemistry and Molecular Biology. In Multiple Drug Resistance. A. Meszaros and G. Balogh (eds), Nova Publishers. Multiple Drug Resistance, 2009, p. 1–24.
- [53] T. Murakami, I. Shibuya, T. Ise, Z.S. Chen, S. Akiyama, M. Nakagawa, et al., Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance, *Int. J. Cancer* 93 (2001) 869–874.
- [54] D. Tavares-Valente, F. Baltazar, R. Moreira, O. Queiros, Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin, *J. Bioenergy Biomembr.* 45 (2013) 467–475.
- [55] K.O. Alfaro, C.-M. Stock, S. Taylor, M. Walsh, A.K. Muddathir, D. Verdusco, et al., Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp, *Cancer Cell Int.* 15 (2015) 71.
- [56] S. Avnet, S. Lemma, M. Cortini, P. Pellegrini, F. Perut, N. Zini, et al., Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism

- of drug resistance, *Oncotarget* (2016), <http://dx.doi.org/10.18632/oncotarget.11503>.
- [57] X.F. Che, C.L. Zheng, S. Akiyama, A. Tomoda, 2-Aminophenoxazine-3-one and 2-amino-4,4 α -dihydro-4 α ,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells, *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 87 (2011) 199–213.
 - [58] S. Shimizu, Y. Eguchi, W. Kamiike, Y. Funahashi, A. Mignon, V. Lacronique, et al., Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux, *Proc. Natl. Acad. Sci. U. S. A.* 95 (1998) 1455–1459.
 - [59] E.L. DiGiammarino, A.S. Lee, C. Cadwell, W. Zhang, B. Bothner, R.C. Ribeiro, et al., A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer, *Nat. Struct. Biol.* 9 (2002) 12–16.
 - [60] S. Matsuyama, J. Llopis, Q.L. Deveraux, R.Y. Tsien, J.C. Reed, Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis, *Nat. Cell Biol.* 2 (2000) 318–325.
 - [61] B.K. Grillo-Hill, C. Choi, M. Jimenez-Vidal, D.L. Barber, Increased H⁺ efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression, *Elife* (2015) 4, <http://dx.doi.org/10.7554/eLife.03270>.
 - [62] S.R. Amith, L. Fliegel, Regulation of the Na⁺/H⁺ exchanger (NHE1) in Breast cancer metastasis, *Cancer Res.* 73 (2013) 1259–1264.
 - [63] S.R. Amith, J.M. Wilkinson, L. Fliegel, Assessing Na⁺/H⁺ exchange and cell effector functionality in metastatic breast cancer, *Biochim. Open.* 2 (2016) 16–23.
 - [64] R.C. Lobo, N.E. Hubbard, P. Damonte, H. Mori, Z. Penzvalto, C. Pham, et al., Glucose uptake and intracellular pH in a mouse model of ductal carcinoma In situ (DCIS) suggests metabolic heterogeneity, *Front. Cell Dev. Biol.* 4 (2016) 93.
 - [65] R.A. Cardone, V. Casavola, S.J. Reshkin, The role of disturbed pH dynamics and the Na⁺/H⁺ exchanger in metastasis, *Nat. Rev. Cancer* 5 (2005) 786–795.
 - [66] M. Abaza, Y.A. Luqmani, The influence of pH and hypoxia on tumor metastasis, *Expert Rev. Anticancer Ther.* 13 (2013) 1229–1242.
 - [67] C. Stock, F.T. Ludwig, A. Schwab, Is the multifunctional Na⁺/H⁺ exchanger isoform 1 a potential therapeutic target in cancer, *Curr. Med. Chem.* 19 (2012) 647–660.
 - [68] T. Torigoe, H. Izumi, T. Ise, T. Murakami, H. Uramoto, H. Ishiguchi, et al., Vacuolar H⁺-ATPase: functional mechanisms and potential as a target for cancer chemotherapy, *Anticancer Drugs* 13 (2002) 237–243.
 - [69] I. Marchiq, J. Pouyssegur, Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H⁺ symporters, *J. Mol. Med. (Berl.)* 94 (2016) 155–171.
 - [70] B.Y. Wang, J. Zhang, J.L. Wang, S. Sun, Z.H. Wang, L.P. Wang, et al., Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer, *J. Exp. Clin. Cancer Res.* 34 (2015) 85.
 - [71] K.O. Alfaro, D. Verduzco, C. Rauch, A.K. Muddathir, H.H. Adil, G.O. Elhassan, et al., Glycolysis, tumor metabolism, cancer growth and dissemination: a new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question, *Oncoscience* 1 (2014) 777–802.
 - [72] F. Aredia, A.I. Scovassi, Multiple effects of intracellular pH modulation in cancer cells, *Cancer Cell Microenviron.* (2014), 1:10–14800/ccm.14136.
 - [73] I. Hrgovic, Z. Glavic, Z. Kovacic, S. Mulic, L. Zunic, Z. Hrgovic, Repeated administration of inhibitors for ion pumps reduce markedly tumor growth in vivo, *Med. Arch.* 68 (2014) 76.
 - [74] C. Sanhueza, J. Araos, L. Naranjo, E. Barros, L. Toledo, M. Subiabre, et al., Are NHE1 and inducible nitric oxide synthase involved in human ovarian cancer? *Pharmacol. Res.* 105 (2016) 183.
 - [75] F. Aredia, A.I. Scovassi, Manipulation of intracellular pH in cancer cells by NHE1 inhibitors, *Protein Pept. Lett.* 23 (2016), <http://dx.doi.org/10.2174/0929866523666161013125536;23>.
 - [76] T. Koltai, Cancer: fundamentals behind pH targeting and the double-edged approach, *Oncotargets Ther.* 9 (2016) 6343–6360.
 - [77] S.K. Parks, J. Chiche, J. Pouyssegur, pH control mechanisms of tumor survival and growth, *J. Cell. Physiol.* 226 (2011) 299–308.
 - [78] S.F. Pedersen, The Na⁺/H⁺ exchanger NHE1 in stress-induced signal transduction: implications for cell proliferation and cell death, *Pflügers Arch.* 452 (2006) 249–259.
 - [79] C. Pinheiro, V. Miranda-Goncalves, A. Longatto-Filho, A.L. Vicente, G.N. Berardinelli, C. Scapulatempo-Neto, et al., The metabolic microenvironment of melanomas: prognostic value of MCT1 and MCT4, *ABBV Cell Cycle* (2016) 1–9.
 - [80] J. Perez-Escuredo, V.F. Van Hee, M. Sboarina, J. Falces, V.L. Payen, L. Pellerin, et al., Monocarboxylate transporters in the brain and in cancer, *Biochim. Biophys. Acta* (2016), <http://dx.doi.org/10.1016/j.bbamer.2016.03.013>.
 - [81] J.W. Choi, Y. Kim, J.H. Lee, Y.S. Kim, Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder, *Urology* 84 (2014) 245 2e9–15.
 - [82] A. Gorbatenko, C.W. Olesen, E. Boedtker, S.F. Pedersen, Regulation and roles of bicarbonate transporters in cancer, *Front. Physiol.* 5 (2014) 130.
 - [83] Y.D. Bhutia, E. Babu, S. Ramachandran, S. Yang, M. Thangaraju, V. Ganapathy, SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms, *Biochem. J.* 473 (2016) 1113–1124.
 - [84] V. Miranda-Goncalves, R.M. Reis, F. Baltazar, Transporters and regulation potential therapeutic targets in glioblastomas, *Curr. Cancer Drug Targets* 16 (2016) 388–399.
 - [85] E. Grillon, R. Farion, M. Reuveni, A. Glidle, C. Remy, J.A. Coles, Spatial profiles of markers of glycolysis, mitochondria, and proton pumps in a rat glioma suggest coordinated programming for proliferation, *BMC Res. Notes* 8 (2015) 207.
 - [86] L.F. Acevedo-Olvera, H. Diaz-Garcia, A. Parra-Barrera, A.A. Caceres-Perez, G. Gutierrez-Iglesias, R. Rangel-Corona, et al., Inhibition of the Na⁺/H⁺ antiporter induces cell death in TF-1 erythroleukemia cells stimulated by the stem cell factor, *Cytokine* 75 (2015) 142–150.
 - [87] I.L. Sun, F.L. Crane, H. Low, Bombesin stimulates transplasma-membrane electron transport by Swiss 3T3 cells, *Biochim. Biophys. Acta* 1221 (1994) 206–210.
 - [88] H. Eagle, Some effects of environmental pH on cellular metabolism and function, *Control Prolif. Anim. Cells* 1 (1974) 1–11.
 - [89] W.H. Moolenaar, Effects of growth factors on intracellular pH regulation, *Annu. Rev. Physiol.* 48 (1986) 363–376.
 - [90] G. L'Allemain, S. Paris, J. Pouyssegur, Growth factor action and intracellular pH regulation in fibroblasts: evidence for a major role of the Na⁺/H⁺ antiporter, *J. Biol. Chem.* 259 (1984) 5809–5815.
 - [91] J. Pouyssegur, A. Franchi, G. L'Allemain, S. Paris, Cytoplasmic pH, a key determinant of growth factor-induced DNA synthesis in quiescent fibroblasts, *FEBS Lett.* 190 (1985) 115–119.
 - [92] C. Brahimi-Horn, J. Pouyssegur, The role of the hypoxia-inducible factor in tumor metabolism growth and invasion, *Bull. Cancer* 93 (2006) E73–80.
 - [93] B. Williams, R.L. Howard, Glucose-induced changes in Na⁺/H⁺ antiporter activity and gene expression in cultured vascular smooth muscle cells. Role of protein kinase, *J. Clin. Invest.* 93 (1994) 2623–2631.
 - [94] R. Perona, R. Serrano, Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump, *Nature* 334 (1988) 438–440.
 - [95] S. Harguindey, J.L. Pedraz, R. Garcia Canero, J. Perez de Diego, E.J. Crague Jr., Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H⁺-mediated unifying approach: pH-related and pH-unrelated mechanisms, *Crit. Rev. Oncog.* 6 (1995) 1–33.
 - [96] C. Aravena, A.R. Beltran, M. Cornejo, V. Torres, E.S. Diaz, E. Guzman-Gutierrez, et al., Potential role of sodium-proton exchangers in the low concentration arsenic trioxide-increased intracellular pH and cell proliferation, *PLoS One* 7 (2012) e51451.
 - [97] S. Grinstein, D. Rotin, M.J. Mason, Na⁺/H⁺ exchange and growth factor-induced cytosolic pH changes: role in cellular proliferation, *Biochim. Biophys. Acta* 988 (1989) 73–97.
 - [98] S. Wakabayashi, P. Fournoux, C. Sartet, J. Pouyssegur, The Na⁺/H⁺ antiporter cytoplasmic domain mediates growth factor signals and controls H⁺-sensing, *Proc. Natl. Acad. Sci. U. S. A.* 89 (1992) 2424–2428.
 - [99] M.J. Gonzalez, J.R. Miranda Massari, J. Duconge, N.H. Riordan, T. Ichim, A.I. Quintero-Del-Rio, et al., The bio-energetic theory of carcinogenesis, *Med. Hypotheses* 79 (2012) 433–439.
 - [100] O.H. Warburg, The prime cause and prevention of cancer. 1969. Lecture delivered to Nobel Laureates on June 30, 1966 at Lindau, Lake Constance, Germany.
 - [101] A. Otto, Warburg effect(s) – a biographical sketch of Otto Warburg and his impacts in tumor metabolism, *Cancer Metab.* 4 (2016) 5, 101186/s40170-016-0145-9.
 - [102] P. Kumar, S. Chand, P.K. Maurya, Quercetin-modulated erythrocyte membrane sodium-hydrogen exchanger during human aging: correlation with ATPase's, *Arch. Physiol. Biochem.* 122 (2016) 141–147.
 - [103] J. Chen, D. Merl, C.W. Peterson, J. Wu, P.Y. Liu, H. Yin, et al., Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA, *PLoS Genet.* 6 (2010) e1001093.
 - [104] R. Radinsky, Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment, *Cancer Metastasis Rev.* 14 (1995) 323–338.
 - [105] T.Y. Reynolds, S. Rockwell, P.M. Glazer, Genetic instability induced by the tumor microenvironment, *Cancer Res.* 56 (1996) 5754–5757.
 - [106] R.K. Singh, R. Tsan, R. Radinsky, Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis, *Clin. Exp. Metastasis* 15 (1997) 140–150.
 - [107] J. Yuan, L. Narayanan, S. Rockwell, P.M. Glazer, Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH, *Cancer Res.* 60 (2000) 4372–4376.
 - [108] Y. Seo, T.J. Kinsella, Essential role of DNA base excision repair on survival in an acidic tumor microenvironment, *Cancer Res.* 69 (2009) 7285–7293.
 - [109] M. Iwaizumi, S. Tseng-Rogenski, J.M. Carethers, Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity, *Mutat. Res.* 747–748 (2013) 19–27.
 - [110] T. Morita, T. Nagaki, I. Fukuda, K. Okumura, Clastogenicity of low pH to various cultured mammalian cells, *Mutat. Res.* 268 (1992) 297–305.
 - [111] M.-T. Dimanche-Boitrel, O. Meurette, S. Jouan-Lanhouet, A. Rebillard, L. Huc, D. Lagadic-Gossman, The acidic extracellular pH: origin, role in tumorigenesis and cancer therapy, in: Dominique Lagadic-Gossman (Ed.), Proton homeostasis and cell death, Research Signpost Publisher, Kerala: India, 2011, pp. 105–118.
 - [112] W. Engstrom, P. Darbre, S. Eriksson, L. Gulliver, T. Hultman, M.V. Karamouzis, et al., The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling, *Carcinogenesis* 36 (Suppl. 1) (2015) S38–60.
 - [113] J. Ochieng, G.N. Nangami, O. Ogunkua, I.R. Miousse, I. Koturbash, V. Odero-Marah, et al., The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis, *Carcinogenesis* 36 (Suppl. 1) (2015) S128–59.

- [114] R. Zhao, D. Oxley, T.S. Smith, G.A. Follows, A.R. Green, D.R. Alexander, DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiporter regulated intracellular pH, *PLoS Biol.* 5 (2007) e1.
- [115] C. Sanhueza, J. Araos, L. Naranjo, R. Villalobos, F. Westermeier, C. Salomon, et al., Modulation of intracellular pH in human ovarian cancer, *Curr. Mol. Med.* 16 (2016) 23–32.
- [116] P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, et al., Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice, *J. Clin. Invest.* 118 (2008) 3930–3942.
- [117] R.A. Gatenby, K. Smallbone, P.K. Maini, F. Rose, J. Averill, R.B. Nagle, et al., Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer, *Br. J. Cancer* 97 (2007) 646–653.
- [118] C. Sanhueza, J. Araos, L. Naranjo, F. Toledo, A.R. Beltran, M.A. Ramirez, et al., Sodium/proton exchanger isoform 1 regulates intracellular pH and cell proliferation in human ovarian cancer, *Biochim. Biophys. Acta* 1863 (2016) 81–91.
- [119] L. Brisson, S.J. Reshkin, J. Gore, S. Roger, pH regulators in invadosomal functioning: proton delivery for matrix tasting, *Eur. J. Cell Biol.* 91 (2012) 847–860.
- [120] J. Orłowski, S. Grinstein, Na⁺/H⁺ exchangers of mammalian cells, *J. Biol. Chem.* 272 (1997) 22373–22376.
- [121] L. Counillon, J. Pouyssegur, The expanding family of eucaryotic Na⁽⁺⁾/H⁽⁺⁾ exchangers, *J. Biol. Chem.* 275 (2000) 1–4.
- [122] J. Lacroix, M. Poet, C. Maehrel, L. Counillon, A mechanism for the activation of the Na/H exchanger NHE-1 by cytoplasmic acidification and mitogens, *EMBO Rep.* 5 (2004) 91–96.
- [123] S. Paris, J. Pouyssegur, Growth factors activate the Na⁺/H⁺ antiporter in quiescent fibroblasts by increasing its affinity for intracellular H⁺, *J. Biol. Chem.* 259 (1984) 10989–10994.
- [124] K. Hardouin, E. Saunier, A. Lemarie, M. Fernier, I. Gallais, C. Helies-Toussaint, et al., The environmental carcinogen benzo[a]pyrene induces a Warburg-like metabolic reprogramming dependent on NHE1 and associated with cell survival, *Sci. Rep.* 6 (2016) 30776.
- [125] E. Pedraz-Cuesta, J. Fredsted, H.H. Jensen, A. Bornebusch, L.N. Nejsun, B.B. Kragelund, et al., Prolactin signaling stimulates invasion via Na⁽⁺⁾/H⁽⁺⁾ exchanger NHE1 in T47D human breast cancer cells, *Mol. Endocrinol.* 30 (2016) 693–708.
- [126] C. Frantz, A. Karydis, P. Nalbant, K.M. Hahn, D.L. Barber, Positive feedback between Cdc42 activity and H⁺ efflux by the Na-H exchanger NHE1 for polarity of migrating cells, *J. Cell Biol.* 179 (2007) 403–410.
- [127] G. Busco, R.A. Cardone, M.R. Greco, A. Bellizzi, M. Colella, E. Antelmi, et al., NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space, *FASEB J.* 24 (2010) 3903–3915.
- [128] H. Izumi, T. Torigoe, H. Ishiguchi, H. Uramoto, Y. Yoshida, M. Tanabe, et al., Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy, *Cancer Treat. Rev.* 29 (2003) 541–549.
- [129] J.J. Provost, M.A. Wallert, Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression, *Chem. Biol. Drug Des.* 81 (2013) 85–101.
- [130] S. Yue Loo, M. Ker Xing Chang, C. Sui Huay Chua, A. Prem Kumar, S. Pervais, Veronique Clement M. NHE-1: a promising target for novel anti-cancer therapeutics, *Curr. Pharm. Des.* 18 (2012) 1372–1382.
- [131] R.G. Mihaila, A minireview on NHE1 inhibitors: a rediscovered hope in oncohematology, *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.* 159 (2015) 519–526.
- [132] M. Sharma, M. Astekar, S. Soi, B. S Manjunatha, D. C Shetty, R. Radhakrishnan. pH Gradient Reversal: An Emerging Hallmark of Cancers. *Recent Pat Anticancer Drug Discov.* (2015); 10: 244–58.
- [133] Harguindey S, Gonzalez Molinillo J, Chinchilla D, Reshkin S, Tomoda A. Further Along a Clinical Protocol Using a Cocktail of PTIs in Human Cancer. *ISPD Abstract Book, 2nd ISPD Meeting, Nice, France, 18–19 2011.*
- [134] P.E. Porporato, S. Dhup, R.K. Dadhich, T. Copetti, P. Sonveaux, Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review, *Front. Pharmacol.* 2 (2011) 49.
- [135] H. Barriere, C. Poujeol, M. Tauc, J.M. Blasi, L. Counillon, P. Poujeol, CFTR modulates programmed cell death by decreasing intracellular pH in Chinese hamster lung fibroblasts, *Am. J. Physiol. Cell Physiol.* 281 (2001) C810–24.
- [136] A. Di Sario, E. Bendia, A. Omenetti, S. De Minicis, M. Marzoni, H.W. Kleemann, et al., Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells, *Dig. Liver Dis.* 39 (2007) 60–69.
- [137] B. He, C. Deng, M. Zhang, D. Zou, M. Xu, Reduction of intracellular pH inhibits the expression of VEGF in K562 cells after targeted inhibition of the Na⁺/H⁺ exchanger, *Leuk. Res.* 31 (2007) 507–514.
- [138] W. Gao, G. Chang, J. Wang, W. Jin, L. Wang, Y. Lin, et al., Inhibition of K562 leukemia angiogenesis and growth by selective Na⁺/H⁺ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF, *Leuk. Res.* 35 (2011) 1506–1511.
- [139] S.J. Reshkin, A. Bellizzi, R.A. Cardone, M. Tommasino, V. Casavola, A. Paradiso, Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na⁺/H⁺ exchanger (NHE) NHE isoform 1 in human breast cancer cells, *Clin. Cancer Res.* 9 (2003) 2366–2373.
- [140] W. Harley, C. Floyd, T. Dunn, X.D. Zhang, T.Y. Chen, M. Hegde, et al., Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas, *Brain Res.* 1363 (2010) 159–169.
- [141] R.A. Cardone, M.R. Greco, K. Zeeberg, A. Zaccagnino, M. Saccomano, A. Bellizzi, et al., A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy, *Neoplasia* 17 (2015) 155–166.
- [142] K.S. Atwal, S.V. O'Neil, S. Ahmad, L. Doweiko, M. Kirby, C.R. Dorso, et al., Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors, *Bioorg. Med. Chem. Lett.* 16 (2006) 4796–4799.
- [143] E. Lastraioli, I. Iorio, A. Arcangeli, Ion channel expression as promising cancer biomarker, *Biochim. Biophys. Acta* 1848 (2015) 2685–2702.
- [144] S. Harguindey, J.L. Pedraz, R.G. Canero, Katin M. Edelfosine, apoptosis, MDR and Na⁺/H⁺ exchanger: induction mechanisms and treatment implications, *Apoptosis* 5 (2000) 87–89.
- [145] Y. Iwata, Y. Katanosaka, T. Hisamitsu, S. Wakabayashi, Enhanced Na⁺/H⁺ exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of P2 receptors, *Am. J. Pathol.* 171 (2007) 1576–1587.
- [146] EspRare. Development of Rimeporide, a sodium-hydrogen exchanger inhibitor, as therapy for patients with Duchenne Muscular Dystrophy. 20th International Congress of the World Muscle Society, Brighton, England, September 30th – October 4th, 2015.
- [147] S.F. Pedersen, C. Stock, Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential, *Cancer Res.* 73 (2013) 1658–1661.
- [148] N. Pertega-Gomes, S. Felisbino, C.E. Massie, J.R. Vizcaino, R. Coelho, C. Sandi, et al., A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy, *J. Pathol.* 236 (2015) 517–530.
- [149] S. Harguindey, Use of Na⁺/H⁺ antiporter inhibitors as a novel approach to cancer treatment, in: *Amiloride and Its Analogs: Unique Cation Transport Inhibitors*, VCH Publishers Inc., New York, 1992, pp. 317–334.
- [150] D. Lagadic-Gossman, L. Huc, V. Lecœur, Alterations of intracellular pH homeostasis in apoptosis: origins and roles, *Cell Death Differ.* 11 (2004) 953–961.
- [151] S. Fais, Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism, *J. Intern. Med.* 267 (2010) 515–525.
- [152] E. Oosterwijk, R.J. Gillies, Targeting ion transport in cancer, *Philos. Trans. R Soc. Lond. B Biol. Sci.* 369 (2014) 20130107.
- [153] A.R. Rowson-Hodel, A.L. Berg, J.H. Wald, J. Hatakeyama, K. VanderVorst, D.A. Curiel, et al., Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells, *Cancer Lett.* (2016), <http://dx.doi.org/10.1016/j.canlet.2016.02.042>.
- [154] J.J. Provost, D. Rastedt, J. Canine, T. Ngyuen, A. Haak, C. Kutz, et al., Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity, *Cell. Oncol.* 35 (2012) 95–110.
- [155] G. Orive, S.J. Reshkin, S. Harguindey, J.L. Pedraz, Hydrogen ion dynamics and the Na⁺/H⁺ exchanger in cancer angiogenesis and antiangiogenesis, *Br. J. Cancer* 89 (2003) 1395–1399.
- [156] L. Munaron, Systems biology of ion channels and transporters in tumor angiogenesis: an omics view, *Biochim. Biophys. Acta* 1848 (2015) 2647–2656.
- [157] S.R. Amith, J.M. Wilkinson, S. Baksh, L. Fliegel, The Na⁽⁺⁾/H⁽⁺⁾ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells, *Oncotarget* 6 (2015) 1262–1275.
- [158] R. Marches, E.S. Vitetta, J.W. Uhr, A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas, *Proc. Natl. Acad. Sci. U. S. A.* 98 (2001) 3434–3439.
- [159] C. Daniel, C. Bell, C. Burton, S. Harguindey, S.J. Reshkin, C. Rauch, The role of proton dynamics in the development and maintenance of multidrug resistance in cancer, *Biochim. Biophys. Acta* 1832 (2013) 606–617.
- [160] M. Walsh, S. Fais, E.P. Spugnini, S. Harguindey, T. Abu Izneid, L. Scacco, et al., Proton pump inhibitors for the treatment of cancer in companion animals, *J. Exp. Clin. Cancer Res.* 34 (2015) 93.
- [161] Harguindey S, Orozco JP, Cuenca M, Fernández MC, Arranz JL. New and powerful NHE1 inhibitors as potential anticancer drugs in bedside oncology: A prospective program of preclinical studies in cats and dogs with spontaneous malignant tumors. *Front Pharmacol [Conference Abstract: 4th Annual Meeting of the International Society of Proton Dynamics in Cancer]* 2014.
- [162] S. Papagerakis, E. Bellile, L.A. Peterson, M. Pliakas, K. Balaskas, S. Selman, et al., Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma, *Cancer Prev. Res. (Phila.)* 7 (2014) 1258–1269.
- [163] B.Y. Wang, J. Zhang, J.L. Wang, S. Sun, Z.H. Wang, L.P. Wang, et al., Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer, *J. Exp. Clin. Cancer Res.* 34 (2015) 85.
- [164] F. Perut, F. Carta, G. Bonuccelli, G. Grisendi, G. Di Pompo, S. Avnet, et al., Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment, *Expert Opin. Ther. Targets* (2015) 1–13.
- [165] M.P. Chu, J.R. Hecht, D. Slamon, Z.A. Wainberg, Y.J. Bang, P.M. Hoff, et al., Association of proton pump inhibitors and capecitabine efficacy in advanced

- gastroesophageal cancer: secondary analysis of the TRIO-013/LOGIC randomized clinical trial, *JAMA Oncol.* (2016).
- [166] V. Ling, Drug resistance and membrane alteration in mutants of mammalian cells, *Can. J. Genet. Cytol.* 17 (1975) 503–515.
- [167] D. Boscoboinik, R.S. Gupta, R.M. Epand, Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells, *Br. J. Cancer* 61 (1990) 568–572.
- [168] O. Thews, B. Gassner, D.K. Kelleher, G. Schwerdt, M. Gekle, Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs, *Neoplasia* 8 (2006) 143–152.
- [169] R.F. Epand, R.M. Epand, R.S. Gupta, E.J. Cragoe Jr., Reversal of intrinsic multidrug resistance in Chinese hamster ovary cells by amiloride analogs, *Br. J. Cancer* 63 (1991) 247–251.
- [170] P.D. Roepe, L.Y. Wei, J. Cruz, D. Carlson, Lower electrical membrane potential and altered pH homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein, *Biochemistry* 32 (1993) 11042–11056.
- [171] F. Thiebaut, S.J. Currier, J. Whitaker, R.P. Haugland, M.M. Gottesman, I. Pastan, et al., Activity of the multidrug transporter results in alkalinization of the cytosol: measurement of cytosolic pH by microinjection of a pH-sensitive dye, *J. Histochem. Cytochem.* 38 (1990) 685–690.
- [172] C. Rauch, A. Pluen, Multi drug resistance-dependent vacuum cleaner functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density, *Eur. Biophys. J.* 36 (2007) 121–131.
- [173] C. Rauch, On the relationship between drug's size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data, *Eur. Biophys. J.* 38 (2009) 537–546.
- [174] S. Taylor, E.P. Spugnini, Y.G. Assaraf, T. Azzarito, C. Rauch, S. Fais, Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach, *Drug Resist. Updat.* 23 (2015) 69–78.
- [175] K.O. Alfarouk, Tumor metabolism, cancer cell transporters, and microenvironmental resistance, *J. Enzyme Inhib. Med. Chem.* (2016) 1–8.
- [176] C. Rauch, Toward a mechanical control of drug delivery: on the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data, *Eur. Biophys. J.* 38 (2009) 829–846.
- [177] T. Wang, G. Liu, R. Wang, The intercellular metabolic interplay between tumor and immune cells, *Front. Immunol.* 5 (2014) 358.
- [178] C.D. Cone Jr., Unified theory on the basic mechanism of normal mitotic control and oncogenesis, *J. Theor. Biol.* 30 (1971) 151–181.
- [179] L.Y. Wei, P.D. Roepe, Low external pH and osmotic shock increase the expression of human MDR protein, *Biochemistry* 33 (1994) 7229–7238.
- [180] J.H. Weisburg, P.D. Roepe, S. Dzekunov, D.A. Scheinberg, Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells, *J. Biol. Chem.* 274 (1999) 10877–10888.
- [181] W. Jin, Q. Li, Y. Lin, Y. Lu, H. Li, L. Wang, et al., Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na⁺/H⁺ exchanger, *Cancer Lett.* 308 (2011) 81–90.
- [182] Q.H. Li, Y. Lu, W.N. Jin, Y.N. Lin, R.H. Hu, X.F. Zhu, et al., [Effect of intracellular acidification on drug resistance of leukemia cells with high P-glycoprotein expression], *Zhonghua Xue Ye Xue Za Zhi.* 30 (2009) 605–609.
- [183] P.D. Roepe, L.Y. Wei, J. Cruz, D. Carlson, Lower electrical membrane potential and altered pH homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein, *Biochemistry* 32 (1993) 11042–11056.
- [184] C. Sauviant, M. Nowak, C. Wirth, B. Schneider, A. Riemann, M. Gekle, et al., Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38, *Int. J. Cancer* 123 (2008) 2532–2542.
- [185] O. Thews, M. Nowak, C. Sauviant, M. Gekle, Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway, in: *Oxygen Transport to Tissue XXXII*, Springer, 2011, pp. 115–122.
- [186] O. Warburg, On respiratory impairment in cancer cells, *Science* 124 (1956) 269–270.
- [187] M.V. Liberti, J.W. Locasale, The Warburg Effect: How Does it Benefit Cancer Cells? *Trends Biochem. Sci.* (2016), <http://dx.doi.org/10.1016/j.tibs.2015.12.001>.
- [188] W. Doppler, R. Jaggi, B. Groner, Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH 3T3 cells causes intracellular alkalinisation and cell-cycle progression, *Gene* 54 (1987) 147–153.
- [189] N. Hagag, J.C. Lacal, M. Graber, S. Aaronson, M.V. Viola, Microinjection of ras p21 induces a rapid rise in intracellular pH, *Mol. Cell. Biol.* 7 (1987) 1984–1988.
- [190] A.S. Relman, Metabolic consequences of acid-base disorders, *Kidney Int.* 1 (1972) 347–359.
- [191] J.M. Calderon-Montano, E. Burgos-Moron, C. Perez-Guerrero, J. Salvador, A. Robles, M. Lopez-Lazaro, Role Of The Intracellular pH In The metabolic switch between oxidative phosphorylation and aerobic glycolysis-relevance to cancer, *WebmedCentralCANCER* 2 (2011) WMC001716.
- [192] C.H.T. Quach, K.-H. Jung, J.H. Lee, J.W. Park, S.H. Moon, Y.S. Cho, et al., Mild alkalization acutely triggers the warburg effect by enhancing hexokinase activity via voltage-Dependent anion channel binding, *PLoS One* 11 (2016) e0159529.
- [193] L.K. Putney, D.L. Barber, Expression profile of genes regulated by activity of the Na-H exchanger NHE1, *BMC Genomics* 5 (2004) 46.
- [194] V.L. Payen, P.E. Porporato, B. Baselet, P. Sonveaux, Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway, *Cell. Mol. Life Sci.* (2015) 1–16.
- [195] N. Lane, W.F. Martin, The origin of membrane bioenergetics, *Cell* 151 (2012) 1406–1416.
- [196] P. Mitchell, Chemiosmotic coupling in oxidative and photosynthetic phosphorylation, *Biol. Rev. Camb. Philos. Soc.* 41 (1966) 445–502.
- [197] P. Mitchell, Chemiosmotic coupling in oxidative and photosynthetic phosphorylation, *Biochim. Biophys. Acta* 2011 (1807) 1507–5388.
- [198] G. Cheng, J. Zielonka, B.P. Dranka, D. McAllister, A.C. Mackinnon Jr., J. Joseph, et al., Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death, *Cancer Res.* 72 (2012) 2634–2644.
- [199] S. Harguindey, E.S. Henderson, C. Naehr, Effects of systemic acidification of mice with Sarcoma 180, *Cancer Res.* 39 (1979) 4364–4371.
- [200] M. Lopez-Lazaro, A new view of carcinogenesis and an alternative approach to cancer therapy, *Mol. Med.* 16 (2010) 144–153.
- [201] R.A. Gatenby, A change of strategy in the war on cancer, *Nature* 459 (2009) 508–509.
- [202] A. Managò, L. Leanza, L. Carraretto, N. Sassi, S. Grancara, R. Quintana-Cabrera, et al., Early effects of the antineoplastic agent salinomycin on mitochondrial function, *Cell. Death. Dis.* 6 (2015) e1930.
- [203] M. Antoszczak, A. Huczynski, Anticancer activity of polyether ionophore-Salinomycin, *Anticancer Agents Med. Chem.* 15 (2015) 575–591.
- [204] C. Naujokat, R. Steinhart, Salinomycin as a drug for targeting human cancer stem cells, *J. Biomed. Biotechnol.* 2012 (2012) 950658, <http://dx.doi.org/10.1155/2012/950658>.
- [205] W. Boehmerle, M. Endres, Salinomycin induces calpain and cytochrome c-mediated neuronal cell death, *Cell. Death. Dis.* 2 (2011) e168.
- [206] W. Boehmerle, H. Muenzfeld, A. Springer, P. Huehnchen, M. Endres, Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice, *J. Mol. Med. (Berl.)* 92 (2014) 889–900.
- [207] A. Huczynski, Salinomycin: a new cancer drug candidate, *Chem. Biol. Drug Des.* 79 (2012) 235–238.
- [208] Rubin H, Fodge D, Interrelationships of glycolysis, sugar transport and the initiation of DNA synthesis in chick embryo cells. In: *Control of Proliferation in Animal Cells* (B Clarkson and R Basega Eds) Cold Spring Harbor Laboratory New York. 1974;1:801–16.
- [209] P. Pellegrini, M. Dyczynski, F.V. Sbrana, M. Karlgren, M. Buoncervello, M. Hagg-Olofsson, et al., Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells, *Oncotarget* (2016), <http://dx.doi.org/10.18632/oncotarget.9601>.
- [210] A.V. Berezhnov, M.P. Soutar, E.I. Fedotova, M.S. Frolova, H. Plun-Favreau, V.P. Zinchenko, et al., Intracellular pH modulates autophagy and mitophagy, *J. Biol. Chem.* 291 (2016) 8701–8708.
- [211] I.J. Furlong, C. Lopez Mediavilla, R. Ascaso, A. Lopez Rivas, M.K. Collins, Induction of apoptosis by valinomycin: mitochondrial permeability transition causes intracellular acidification, *Cell Death Differ.* 5 (1998) 214–221.
- [212] J.X. Pan, K. Ding, C.Y. Wang, Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells, *Chin J. Cancer.* 31 (2012) 178–184.
- [213] Y. Li, P.K. Li, M.J. Roberts, R.C. Arend, R.S. Samant, D.J. Buchsbaum, Multi-targeted therapy of cancer by niclosamide: a new application for an old drug, *Cancer Lett.* 349 (2014) 8–14.
- [214] B.D. Fonseca, G.H. Diering, M.A. Bidinosti, K. Dalal, T. Alain, A.D. Balgi, et al., Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling, *J. Biol. Chem.* 287 (2012) 17530–17545.
- [215] S.S. Brar, C. Grigg, K.S. Wilson, W.D. Holder Jr., D. Dreau, C. Austin, et al., Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease, *Mol. Cancer Ther.* 3 (2004) 1049–1060.
- [216] J. Navratilova, T. Hankeova, P. Benes, J. Smarda, Acidic pH of tumor microenvironment enhances cytotoxicity of the disulfiram/Cu²⁺ complex to breast and colon cancer cells, *Chemotherapy* 59 (2013) 112–120.
- [217] A. Martirosyan, J.W. Clendening, C.A. Goard, L.Z. Penn, Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance, *BMC Cancer* 10 (2010) 103.
- [218] D. Perez-Sala, D. Collado-Escobar, F. Molinedo, Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease, *J. Biol. Chem.* 270 (1995) 6235–6242.
- [219] Bakar NS JS, Kamali F, Brown CDA. Statin Inhibition of Monocarboxylate Transporter (MCT)-Mediated Lactate Transport in HK-2Cells. *Proc British Pharmacol Soc Vol10, Issue4, abst085P*.
- [220] E. Gottfried, S.A. Lang, K. Renner, A. Bosserhoff, W. Gronwald, M. Rehli, et al., New aspects of an old drug—diclofenac targets MYC and glucose metabolism in tumor cells, *PLoS One* 8 (2013) e66987.
- [221] I. Marchiq, R. Le Floch, D. Roux, M.P. Simon, J. Pouyssegur, Genetic disruption of lactate/H⁺ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin, *Cancer Res.* 75 (2015) 171–180.

- [222] J.L. Bosco, S. Antonsen, H.T. Sorensen, L. Pedersen, T.L. Lash, Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark, *Cancer Epidemiol. Biomarkers Prev.* 20 (2011) 101–111.
- [223] P.J. Goodwin, J.A. Ligibel, V. Stambolic, Metformin in breast cancer: time for action, *J. Clin. Oncol.* 27 (2009) 3271–3273.
- [224] J.A. Menendez, B. Martin-Castillo, J. Joven, Metformin and cancer: quo vadis et cui bono? *Oncotarget* (2016), <http://dx.doi.org/10.18632/oncotarget.10262>.
- [225] J.R. Doherty, C. Yang, K.E. Scott, M.D. Cameron, M. Fallahi, W. Li, et al., Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis, *Cancer Res.* 74 (2014) 908–920.
- [226] V. Miranda-Goncalves, M. Honavar, C. Pinheiro, O. Martinho, M.M. Pires, C. Pinheiro, et al., Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets, *Neuro Oncol.* 15 (2013) 172–188.
- [227] S. Peppicelli, A. Toti, E. Giannoni, F. Bianchini, F. Margheri, M. Del Rosso, et al., Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation, *ABV Cell Cycle* 15 (2016) 1908–1918.
- [228] J.M. Calderon-Montano, E. Burgos-Moron, M.L. Orta, D. Maldonado-Navas, I. Garcia-Dominguez, M. Lopez-Lazaro, Evaluating the cancer therapeutic potential of cardiac glycosides, *BioMed Res. Int.* 2014 (2014) 794930.
- [229] M. Slingerland, C. Cerella, H.J. Guchelaar, M. Diederich, H. Gelderblom, Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials, *Invest. New Drugs* 31 (2013) 1087–1094.
- [230] D.G. Garcia, L.M. Amorim, M.V. de Castro Faria, A.S. Freire, R.E. Santelli, C.O. Da Fonseca, et al., The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor, *Mol. Cell. Biochem.* 345 (2010) 29–34.
- [231] S.S. Clark, S.M. Perman, M.B. Sahin, G.J. Jenkins, J.A. Elegbede, Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest, *Leukemia* 16 (2002) 213–222.
- [232] C. Fonseca, R. Teixeira, R. Ramina, G. Kovalski, J. Silva, J. Nagel, et al., Case of advanced recurrent glioblastoma successfully treated with monoterpenic perillyl alcohol by intranasal administration, *J. Cancer Ther.* 2 (2011) 16–21.
- [233] C.O. Da Fonseca, I.P. Soares, D.S. Clemençon, S. Rochlin, L. Cardeman, T. Quirico-Santos, Perillyl alcohol inhalation concomitant with oral temozolomide halts progression of recurrent inoperable glioblastoma: a case report, *J. Histol. Histopathol.* (2015), <http://dx.doi.org/10.7243/2055-091x-2-12>.
- [234] Y.H. Ko, H.A. Verhoeven, M.J. Lee, D.J. Corbin, T.J. Vogl, P.L. Pedersen, A translational study case report on the small molecule energy blocker 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside, *J. Bioenergy Biomembr.* 44 (2012) 163–170.
- [235] Y.H. Ko, B.L. Smith, Y. Wang, M.G. Pomper, D.A. Rini, M.S. Torbenson, et al., Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP, *Biochem. Biophys. Res. Commun.* 324 (2004) 269–275.
- [236] J. Azevedo-Silva, O. Queiros, A. Ribeiro, F. Baltazar, K.H. Young, P.L. Pedersen, et al., The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH, *Biochem. J.* 467 (2015) 247–258.
- [237] E. Calvino, M.C. Estan, C. Sanchez-Martin, R. Brea, E. de Blas, C. Boyano-Adanez Mdel, et al., Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation, *J. Pharmacol. Exp. Ther.* 348 (2014) 324–335.
- [238] A. Kumar, S. Kant, S.M. Singh, Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: implication of altered glucose metabolism, pH homeostasis and cell survival regulation, *Chem. Biol. Interact.* 199 (2012) 29–37.
- [239] D. Flavin, Medullary thyroid carcinoma relapse reversed with dichloroacetate: a case report, *Oncol. Lett.* 1 (2010) 889–891.
- [240] M.J. Boyer, I.F. Tannock, Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions, *Cancer Res.* 52 (1992) 4441–4447.
- [241] I.F. Tannock, D. Rotin, Acid pH in tumors and its potential for therapeutic exploitation, *Cancer Res.* 49 (1989) 4373–4384.
- [242] J. Luo, I.F. Tannock, Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy, *Br. J. Cancer* 70 (1994) 617–624.
- [243] R.P. Maidorn, E.J. Cragoe Jr., I.F. Tannock, Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy, *Br. J. Cancer* 67 (1993) 297–303.
- [244] K. Hasuda, C. Lee, I.F. Tannock, Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH, *Oncol. Res.* 6 (1994) 259–268.
- [245] M. Yamagata, I.F. Tannock, The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects, *Br. J. Cancer* 73 (1996) 1328–1334.
- [246] L.B. Margolis, I.Y. Novikova, I.A. Rozovskaya, V.P. Skulachev, K+/H+-antiporter nigericin arrests DNA synthesis in Ehrlich ascites carcinoma cells, *Proc. Natl. Acad. Sci. U. S. A.* 86 (1989) 6626–6629.
- [247] K.G. Hofer, N.F. Mivechi, Tumor cell sensitivity to hyperthermia as a function of extracellular and intracellular pH, *J. Natl. Cancer Inst.* 65 (1980) 621–625.
- [248] J.C. Lyons, G.E. Kim, C.W. Song, Modification of intracellular pH and thermosensitivity, *Radiat. Res.* 129 (1992) 79–87.
- [249] C.W. Song, J.C. Lin, J.C. Lyons, Antitumor effect of interleukin 1 alpha in combination with hyperthermia, *Cancer Res.* 53 (1993) 324–328.
- [250] J.C. Liu, M.H. Fox, Modification of intracellular pH and thermotolerance development by amiloride, *Int. J. Hyperthermia* 11 (1995) 511–522.
- [251] F.F. Liu, K. Diep, R.P. Hill, The relationship between thermosensitivity and intracellular pH in cells deficient in Na+/H+ antiport function, *Radiother. Oncol.* 40 (1996) 75–83.
- [252] R. Kitai, M. Kabuto, T. Kubota, H. Kobayashi, H. Matsumoto, S. Hayashi, et al., Sensitization to hyperthermia by intracellular acidification of C6 glioma cells, *J. Neurooncol.* 39 (1998) 197–203.
- [253] J.C. Lyons, B.D. Ross, C.W. Song, Enhancement of hyperthermia effect in vivo by amiloride and DIDS, *Int. J. Radiat. Oncol. Biol. Phys.* 25 (1993) 95–103.
- [254] L.E. Gerweck, Tumor pH: implications for treatment and novel drug design, *Semin. Radiat. Oncol.* 8 (1998) 176–182.
- [255] C.W. Song, R. Griffin, H.J. Park, Influence of tumor pH on therapeutic response, in: *Cancer Drug Resistance*, Springer, 2006, pp. 21–42, http://dx.doi.org/10.1007/978-1-59745-035-5_2.
- [256] P. Bougnoux, N. Hajjaji, M.N. Ferrasson, B. Giraudeau, C. Couet, O. Le Floch, Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial, *Br. J. Cancer* 101 (2009) 1978–1985.
- [257] P. Bougnoux, N. Hajjaji, K. Maheo, C. Couet, S. Chevalier, Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth, *Prog. Lipid Res.* 49 (2010) 76–86.
- [258] R. Wannous, E. Bon, K. Maheo, C. Goupille, J. Chamouton, P. Bougnoux, et al., PPARbeta mRNA expression, reduced by n-3 PUFA diet in mammary tumor, controls breast cancer cell growth, *Biochim. Biophys. Acta* 1831 (2013) 1618–1625.
- [259] L. Chauvin, C. Goupille, C. Blanc, M. Pinault, I. Domingo, C. Guimaraes, et al., Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCepsilon/delta-induced ERK pathways, *Biochim. Biophys. Acta* 1861 (2016) 380–390.
- [260] L. Brisson, L. Gillet, S. Calaghan, P. Besson, J. Le Guennec, S. Roger, et al., NaV1: 5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H+ efflux in caveolae, *Oncogene* 30 (2011) 2070–2076.
- [261] L. Brisson, V. Driffort, L. Benoist, M. Poet, L. Counillon, E. Antelmi, et al., NaV1.5 Na(+) channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia, *J. Cell Sci.* 126 (2013) 4835–4842.
- [262] R. Wannous, E. Bon, L. Gillet, J. Chamouton, G. Weber, L. Brisson, et al., Suppression of PPARβ, and DHA treatment, inhibit NaV1. 5 and NHE-1 pro-invasive activities, *Pflügers Arch.-Eur. J. Physiol.* 467 (2014) 1249–1259.
- [263] L. Gillet, S. Roger, P. Bougnoux, J.Y. Le Guennec, P. Besson, Beneficial effects of omega-3 long-chain fatty acids in breast cancer and cardiovascular diseases: voltage-gated sodium channels as a common feature, *Biochimie* 93 (2011) 4–6.
- [264] M. Lopez-Lazaro, Digoxin, HIF-1, and cancer, *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) E26.
- [265] M. Lopez-Lazaro, N. Pastor, S.S. Azrak, M.J. Ayuso, C.A. Austin, F. Cortes, Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients, *J. Nat. Prod.* 68 (2005) 1642–1645.
- [266] M. Lopez-Lazaro, Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved, *Expert Opin. Ther. Targets* 11 (2007) 1043–1053.
- [267] H.A. Elbaz, T.A. Stueckle, W. Tse, Y. Rojanasakul, C.Z. Dinu, Digitoxin and its analogs as novel cancer therapeutics, *Exp. Hematol. Oncol.* 1 (2012) 4.
- [268] T. Koltai, Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs, *F1000Research* 4 (2015).
- [269] Lasse Leino JL. Anti-proliferative pharmaceutical composition. US Patent 8338475 B2, 2012.
- [270] Kadri NB, Gdovin M, Alyassin N, Avila J, Cruz A, Cruz L, et al. Photodynamic acidification therapy to reduce triple negative breast cancer growth in vivo. ASCO Annual Meeting Proceedings vol 34, N° 15. suppl (May 20 Supplement) 2016, p. e12574.
- [271] M. Obara, M. Szeliga, J. Albrecht, Regulation of pH in the mammalian central nervous system under normal and pathological conditions: facts and hypotheses, *Neurochem. Int.* 52 (2008) 905–919.
- [272] Z.-G. Xiong, G. Pignataro, M. Li, R.P. Chang S-y Simon, Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases, *Curr. Opin. Pharmacol.* 8 (2008) 25–32.
- [273] A. Schwab, C. Stock, Ion channels and transporters in tumour cell migration and invasion, *Philos. Trans. R Soc. Lond. B Biol. Sci.* 369 (2014) 20130102.
- [274] A. Litan, S.A. Langhans, Cancer as a channelopathy: ion channels and pumps in tumor development and progression, *Front. Cell. Neurosci.* 9 (2015) 86.
- [275] F. Lang, C. Stournaras, Ion channels in cancer: future perspectives and clinical potential, *Philos. Trans. R Soc. Lond. B Biol. Sci.* 369 (2014) 20130108.
- [276] P. Besson, V. Driffort, E. Bon, F. Gradek, S. Chevalier, S. Roger, How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells, *Biochim. Biophys. Acta* 1848 (2015) 2493–2501.
- [277] S. Roger, L. Gillet, J.Y. Le Guennec, P. Besson, Voltage-gated sodium channels and cancer: is excitability their primary role? *Front. Pharmacol.* 6 (2015) 152.
- [278] C. Stock, F.T. Ludwig, P.J. Hanley, A. Schwab, Roles of ion transport in control of cell motility, *Compr. Physiol.* 3 (2013) 59–119.

- [279] N. Prevarskaya, H. Ouadid-Ahidouch, R. Skryma, Y. Shuba, Remodelling of Ca^{2+} transport in cancer: how it contributes to cancer hallmarks? *Philos. Trans. R Soc. Lond. B Biol. Sci.* 369 (2014) 20130097.
- [280] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, *Cell* 100 (2000) 57–70.
- [281] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, *Cell* 144 (2011) 646–674.
- [282] T.E. DeCoursey, Voltage-gated proton channels: molecular biology, physiology, and pathophysiology of the H(V) family, *Physiol. Rev.* 93 (2013) 599–652.
- [283] S. Kellenberger, L. Schild, International Union of Basic and Clinical Pharmacology XCI. structure, function, and pharmacology of acid-sensing ion channels and the epithelial Na^+ channel, *Pharmacol. Rev.* 67 (2015) 1–35.
- [284] M.J. Caterina, M.A. Schumacher, M. Tominaga, T.A. Rosen, J.D. Levine, D. Julius, The capsaicin receptor: a heat-activated ion channel in the pain pathway, *Nature* 389 (1997) 816–824.
- [285] M. Tominaga, M.J. Caterina, A.B. Malmberg, T.A. Rosen, H. Gilbert, K. Skinner, et al., The cloned capsaicin receptor integrates multiple pain-producing stimuli, *Neuron* 21 (1998) 531–543.
- [286] Y.Y. Wang, R.B. Chang, E.R. Liman, TRPA1 is a component of the nociceptive response to CO_2 , *J. Neurosci.* 30 (2010) 12958–12963.
- [287] Y.Y. Wang, R.B. Chang, S.D. Allgood, W.L. Silver, E.R. Liman, A TRPA1-dependent mechanism for the pungent sensation of weak acids, *J. Gen. Physiol.* 137 (2011) 493–505.
- [288] S. Feliciangeli, F.C. Chatelain, D. Bichet, F. Lesage, The family of K2P channels: salient structural and functional properties, *J. Physiol.* 593 (2015) 2587–2603.
- [289] F.V. Sepulveda, L. Pablo Cid, J. Teulon, M.I. Niemeyer, Molecular aspects of structure, gating, and physiology of pH-sensitive background K2P and Kir K⁺-transport channels, *Physiol. Rev.* 95 (2015) 179–217.
- [290] G.C. Tombaugh, G.G. Somjen, Effects of extracellular pH on voltage-gated Na^+ , K^+ and Ca^{2+} currents in isolated rat CA1 neurons, *J. Physiol.* 493 (Pt 3) (1996) 719–732.
- [291] S.F. Pedersen, E.K. Hoffmann, I. Novak, Cell volume regulation in epithelial physiology and cancer, *Front. Physiol.* 4 (2013) 233.
- [292] V. De-la-Rosa, E. Suarez-Delgado, G.E. Rangel-Yescas, L.D. Islas, Currents through Hv1 channels deplete protons in their vicinity, *J. Gen. Physiol.* 147 (2016) 127–136.
- [293] Y. Wang, S.J. Li, J. Pan, Y. Che, J. Yin, Q. Zhao, Specific expression of the human voltage-gated proton channel Hv1 in highly metastatic breast cancer cells, promotes tumor progression and metastasis, *Biochem. Biophys. Res. Commun.* 412 (2011) 353–359.
- [294] Y. Wang, S.J. Li, X. Wu, Y. Che, Q. Li, Clinicopathological and biological significance of human voltage-gated proton channel Hv1 protein overexpression in breast cancer, *J. Biol. Chem.* 287 (2012) 13877–13888.
- [295] Y. Wang, X. Wu, Q. Li, S. Zhang, S.J. Li, Human voltage-gated proton channel hv1: a new potential biomarker for diagnosis and prognosis of colorectal cancer, *PLoS One* 8 (2013) e70550.
- [296] Tombola, F. Small molecule inhibitors of the Hv1 channel as chemotherapeutics and anti-inflammatory agents – Tech ID: 23594/UC Case 2013-371-0.
- [297] W.A. Catterall, Voltage-gated sodium channels at 60: structure, function and pathophysiology, *J. Physiol.* 590 (2012) 2577–2589.
- [298] M. Mantegazza, G. Curia, G. Biagini, D.S. Ragsdale, M. Avoli, Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders, *Lancet Neurol.* 9 (2010) 413–424.
- [299] W.J. Brackenbury, Voltage-gated sodium channels and metastatic disease, *Channels (Austin)* 6 (2012) 352–361.
- [300] S. Roger, M. Potier, C. Vandier, P. Besson, J.Y. Le Guennec, Voltage-gated sodium channels: new targets in cancer therapy, *Curr. Pharm. Des.* 12 (2006) 3681–3695.
- [301] S.P. Fraser, J.K. Diss, A.M. Chioni, M.E. Mycielska, H. Pan, R.F. Yamaci, et al., Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis, *Clin. Cancer Res.* 11 (2005) 5381–5389.
- [302] M. Yang, D.J. Kozminski, L.A. Wold, R. Modak, J.D. Calhoun, L.L. Isom, et al., Therapeutic potential for phenytoin: targeting $\text{Na}^+(\text{v})1.5$ sodium channels to reduce migration and invasion in metastatic breast cancer, *Breast Cancer Res. Treat.* 134 (2012) 603–615.
- [303] L. Gillet, S. Roger, P. Besson, F. Lecaillie, J. Gore, P. Bougnoux, et al., Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells, *J. Biol. Chem.* 284 (2009) 8680–8691.
- [304] F. Lecaillie, J. Kaleta, D. Brömme, Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design, *Chem. Rev.* 102 (2002) 4459–4488.
- [305] M. Yang, W.J. Brackenbury, Membrane potential and cancer progression, *Front. Physiol.* 4 (2013) 185.
- [306] C. Fairhurst, I. Watt, F. Martin, M. Bland, W.J. Brackenbury, Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database, *BMJ Open* 4 (2014) e006604.
- [307] C.P. Taylor, B.S. Meldrum, Na^+ channels as targets for neuroprotective drugs, *Trends Pharmacol. Sci.* 16 (1995) 309–316.
- [308] V. Driffort, L. Gillet, E. Bon, S. Marionneau-Lambot, T. Oullier, V. Joulin, et al., Ranolazine inhibits $\text{NaV}1.5$ -mediated breast cancer cell invasiveness and lung colonization, *Mol. Cancer* 13 (2014) 264.
- [309] M. Nelson, M. Yang, A.A. Dowle, J.R. Thomas, W.J. Brackenbury, The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis, *Mol. Cancer* 14 (2015) 13.
- [310] S. Roger, J.Y. Le Guennec, P. Besson, Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastatic breast cancer cell line, *Br. J. Pharmacol.* 141 (2004) 610–615.
- [311] D.T. Baptista-Hon, F.M. Robertson, G.B. Robertson, S.J. Owen, G.W. Rogers, E.L. Lydon, et al., Potent inhibition by ropivacaine of metastatic colon cancer SW620 cell invasion and $\text{NaV}1.5$ channel function, *Br. J. Anaesth.* 113 (Suppl. 1) (2014) i39–i48.
- [312] X. Li, D. Prins, M. Michalak, L. Fiegel, Calmodulin-dependent binding to the NHE1 cytosolic tail mediates activation of the Na^+/H^+ exchanger by Ca^{2+} and endothelin, *Am. J. Physiol. Cell Physiol.* 305 (2013) C1161–9.
- [313] S. Koster, T. Pavlov-Keller, W. Kuhlbrandt, O. Yildiz, Structure of human Na^+/H^+ exchanger NHE1 regulatory region in complex with calmodulin and Ca^{2+} , *J. Biol. Chem.* 286 (2011) 40954–40961.
- [314] D. Ibarreta, E. Urcelay, R. Parrilla, M.S. Ayuso, Distinct pH homeostatic features in lymphoblasts from Alzheimer's disease patients, *Ann. Neurol.* 44 (1998) 216–222.
- [315] D.W. Choi, Calcium: still center-stage in hypoxic-ischemic neuronal death, *Trends Neurosci.* 18 (1995) 58–60.
- [316] C. Peers, J.L. Scragg, J.P. Boyle, I.M. Fearon, S.C. Taylor, K.N. Green, et al., A central role for ROS in the functional remodelling of L-type Ca^{2+} channels by hypoxia, *Philos. Trans. R Soc. Lond. B Biol. Sci.* 360 (2005) 2247–2254.
- [317] B.S. Meldrum, Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia, *Ann. N.Y. Acad. Sci.* 757 (1995) 492–505.
- [318] R. de Ceglia, L. Chaabane, E. Biffi, A. Bergamaschi, G. Ferrigno, S. Amadio, et al., Down-sizing of neuronal network activity and density of presynaptic terminals by pathological acidosis are efficiently prevented by Diminazene Aceturate, *Brain Behav. Immun.* 45 (2015) 263–276.
- [319] F.J. Urbano, N.G. Lino, C.M. Gonzalez-Inchauspe, L.E. Gonzalez, N. Coletti, L.G. Vattino, et al., Acid-sensing ion channels 1a (ASIC1a) inhibit neuromuscular transmission in female mice, *Am. J. Physiol. Cell Physiol.* 306 (2014) C396–406.
- [320] K.-I. Takahashi, D.R. Copenhagen, Modulation of neuronal function by intracellular pH, *Neurosci. Res.* 24 (1996) 109–116.
- [321] S.W. Kuo, M. Jiang, C. Heckman, Potential involvement of intracellular pH in a mouse model of amyotrophic lateral sclerosis, *Amyotroph Lateral Scler Frontotemporal Degener.* 15 (2014) 151–153.
- [322] J.C. Dodge, C.M. Treleaven, J.A. Fidler, T.J. Tamsett, C. Bao, M. Searles, et al., Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 10812–10817.
- [323] M. Nedergaard, R.P. Kraig, J. Tanabe, W.A. Pulsinelli, Dynamics of interstitial and intracellular pH in evolving brain infarct, *Am. J. Physiol.* 260 (1991) R581–8.
- [324] M. Nedergaard, S.A. Goldman, S. Desai, W.A. Pulsinelli, Acid-induced death in neurons and glia, *J. Neurosci.* 11 (1991) 2489–2497.
- [325] B.K. Siesjö, K. Katsura, T. Kristian, Acidosis-related damage, *Adv. Neurol.* 71 (1996) 209–233, discussion 34–6.
- [326] Z.G. Xiong, X.M. Zhu, X.P. Chu, M. Minami, J. Hey, W.L. Wei, et al., Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels, *Cell* 118 (2004) 687–698.
- [327] T.W. Sherwood, K.G. Lee, M.G. Gormley, C.C. Askwith, Heteromeric acid-sensing ion channels (ASICs) composed of ASIC2b and ASIC1a display novel channel properties and contribute to acidosis-induced neuronal death, *J. Neurosci.* 31 (2011) 9723–9734.
- [328] P. Quintana, D. Soto, O. Poirot, M. Zonouzi, S. Kellenberger, D. Muller, et al., Acid-sensing ion channel 1a drives AMPA receptor plasticity following ischaemia and acidosis in hippocampal CA1 neurons, *J. Physiol.* 593 (2015) 4373–4386.
- [329] J.A. Wemmie, R.J. Taugher, C.J. Kreple, Acid-sensing ion channels in pain and disease, *Nat. Rev. Neurosci.* 14 (2013) 461–471.
- [330] M. Chesler, Regulation and modulation of pH in the brain, *Physiol. Rev.* 83 (2003) 1183–1221.
- [331] K.C. Kondapalli, H. Prasad, R. Rao, An inside job: how endosomal $\text{Na}^+(\text{H}^+)$ exchangers link to autism and neurological disease, *Front. Cell. Neurosci.* 8 (2014) 172.
- [332] B. Haenisch, K. von Holt, B. Wiese, J. Prokein, C. Lange, A. Ernst, et al., Risk of dementia in elderly patients with the use of proton pump inhibitors, *Eur. Arch. Psychiatry Clin. Neurosci.* 265 (2015) 419–428.
- [333] I.S. Jang, M.S. Brodwick, Z.M. Wang, H.J. Jeong, B.J. Choi, N. Akaike, The Na^+/H^+ exchanger is a major pH regulator in GABAergic presynaptic nerve terminals synapsing onto rat CA3 pyramidal neurons, *J. Neurochem.* 99 (2006) 1224–1236.
- [334] H. Hamakawa, J. Murashita, N. Yamada, T. Inubushi, N. Kato, T. Kato, Reduced intracellular pH in the basal ganglia and whole brain measured by ^{31}P -MRS in bipolar disorder, *Psychiatry Clin. Neurosci.* 58 (2004) 82–88.
- [335] V.A. Ruffin, A.I. Salameh, W.F. Boron, M.D. Parker, Intracellular pH regulation by acid-base transporters in mammalian neurons, *Front. Physiol.* 5 (2014) 43.
- [336] Behrens MI, Ponce DP, Roe CM, Salech F. Common Biological Mechanisms in Alzheimer's Disease and Cancer. 2014. In: *Advances in Alzheimer's Research* vol.2, 2014, 33–57. (Ed). D.K.Lahiri. Chapter 2.
- [337] G.L. Semenza, Regulation of cancer cell metabolism by hypoxia-inducible factor 1, *Semin. Cancer Biol.* 19 (2009) 12–16.

- [338] A. Quaegebeur, P. Carmeliet, Oxygen sensing: a common crossroad in cancer and neurodegeneration, *Curr. Top. Microbiol. Immunol.* 345 (2010) 71–103.
- [339] J.W. Deitmer, C.R. Rose, pH regulation and proton signalling by glial cells, *Prog. Neurobiol.* 48 (1996) 73–103.
- [340] U. Flögel, W. Willker, D. Leibfritz, Regulation of intracellular pH in neuronal and glial tumour cells, studied by multinuclear NMR spectroscopy, *NMR Biomed.* 7 (1994) 157–166.
- [341] C.S. Atwood, R.D. Moir, X. Huang, R.C. Scarpa, N.M. Bacarra, D.M. Romano, et al., Dramatic aggregation of Alzheimer β by Cu(II) is induced by conditions representing physiological acidosis, *J. Biol. Chem.* 273 (1998) 12817–12826.
- [342] J.E. Torres-Lopez, C.G. Guzman-Priego, H.I. Rocha-Gonzalez, V. Granados-Soto, Role of NHE1 in nociception, *Pain Res. Treat.* 2013 (2013) 217864.
- [343] J. Zhang, H. Peng, S.C. Veasey, J. Ma, G.F. Wang, K.W. Wang, Blockade of Na⁺/H⁺ exchanger type 3 causes intracellular acidification and hyperexcitability via inhibition of pH-sensitive K⁺ channels in chemosensitive respiratory neurons of the dorsal vagal nucleus in rats, *Neurosci. Bull.* 30 (2014) 43–52.
- [344] J.E. Yuste, E. Tarragon, C.M. Campuzano, F. Ros-Bernal, Implications of glial nitric oxide in neurodegenerative diseases, *Front. Cell. Neurosci.* 9 (2015) 322.
- [345] A.K. Raina, A. Hochman, H. Ickes, X. Zhu, O. Ogawa, A.D. Cash, et al., Apoptotic promoters and inhibitors in Alzheimer's disease: who wins out, *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 27 (2003) 251–254.
- [346] B.K. Lee, Y.S. Jung, The Na⁺/H⁺ exchanger-1 inhibitor cariporide prevents glutamate-induced necrotic neuronal death by inhibiting mitochondrial Ca²⁺ overload, *J. Neurosci. Res.* 90 (2012) 860–869.
- [347] W. Gomm, K. von Holt, F. Thome, K. Broich, W. Maier, A. Fink, et al., Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis, *JAMA Neurol.* 73 (2016) 410–416.
- [348] J.C. Durham-Lee, V.U. Mokkapatil, K.M. Johnson, O. Nesic, Amiloride improves locomotor recovery after spinal cord injury, *J. Neurotrauma* 28 (2011) 1319–1326.
- [349] A.M. Tolkovsky, C.D. Richards, Na⁺/H⁺ exchange is the major mechanism of pH regulation in cultured sympathetic neurons: measurements in single cell bodies and neurites using a fluorescent pH indicator, *Neuroscience* 22 (1987) 1093–1102.
- [350] P. Cengiz, D.B. Kintner, V. Chanana, H. Yuan, E. Akture, P. Kendigelen, et al., Sustained Na⁺/H⁺ exchanger activation promotes gliotransmitter release from reactive hippocampal astrocytes following oxygen-glucose deprivation, *PLoS One* 9 (2014) e84294.
- [351] R. Cacabelos, R. Martinez-Bouza, J.C. Carril, L. Fernandez-Novoa, V. Lombardi, I. Carrera, et al., Genomics and pharmacogenomics of brain disorders, *Curr. Pharm. Biotechnol.* 13 (2012) 674–725.
- [352] R. Cacabelos, P. Cacabelos, C. Torrellas, I. Tellado, J.C. Carril, Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development, *Methods Mol. Biol.* 1175 (2014) 323–556.
- [353] R. Cacabelos, C. Torrellas, I. Carrera, Opportunities in pharmacogenomics for the treatment of Alzheimer's disease, *Future Neurol.* 10 (2015) 229–252.
- [354] M.K. Collins, G.R. Perkins, G. Rodriguez-Tarduchy, M.A. Nieto, A. Lopez-Rivas, Growth factors as survival factors: regulation of apoptosis, *Bioessays* 16 (1994) 133–138.
- [355] E. Anitua, M. Sanchez, G. Orive, I. Andia, The potential impact of the preparation rich in growth factors (PRGF) in different medical fields, *Biomaterials* 28 (2007) 4551–4560.
- [356] C. Campos, N.B. Rocha, E. Lattari, F. Paes, A.E. Nardi, S. Machado, Exercise-induced neuroprotective effects on neurodegenerative diseases: the key role of trophic factors, *Expert Rev. Neurother.* 16 (2016) 723–734.
- [357] E.C. Jenkins, S. Debnath, S. Gundry, U. Uyar, J.E. Fata, Intracellular pH regulation by Na⁺/H⁺ exchanger-1 (NHE1) is required for growth factor-induced mammary branching morphogenesis, *Dev. Biol.* 365 (2012) 71–81.
- [358] E. Ma, G.G. Haddad, Expression and localization of Na⁺/H⁺ exchangers in rat central nervous system, *Neuroscience* 79 (1997) 591–603.
- [359] A. Di Sario, E. Bendia, G. Svegliati Baroni, F. Ridolfi, L. Bolognini, G. Feliciangeli, et al., Intracellular pathways mediating Na⁺/H⁺ exchange activation by platelet-derived growth factor in rat hepatic stellate cells, *Gastroenterology* 116 (1999) 1155–1166.
- [360] J. Devesa, L. Lima, J.A. Tresguerres, Neuroendocrine control of growth hormone secretion in humans, *Trends Endocrinol. Metab.* 3 (1992) 175–183.
- [361] D. Rudman, M.H. Kutner, C.M. Rogers, M.F. Lubin, G.A. Fleming, R.P. Bain, Impaired growth hormone secretion in the adult population: relation to age and adiposity, *J. Clin. Invest.* 67 (1981) 1361–1369.
- [362] F. Nyberg, M. Hallberg, Growth hormone and cognitive function, *Nat. Rev. Endocrinol.* 9 (2013) 357–365.
- [363] J. Devesa, H. Lema, E. Zas, B. Munin, P. Taboada, P. Devesa, Learning and memory recovery in a young girl treated with growth hormone and neurorehabilitation, *J. Clin. Med.* 5 (2016) 14.
- [364] H. Zhang, M. Han, X. Zhang, X. Sun, F. Ling, The effect and mechanism of growth hormone replacement on cognitive function in rats with traumatic brain injury, *PLoS One* 9 (2014) e108518.
- [365] P. Devesa, F. Agasse, S. Xapelli, C. Almenglo, J. Devesa, J.O. Malva, et al., Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice, *BMC Neurosci.* 15 (2014) 100.
- [366] P. Devesa, P. Reimunde, R. Gallego, J. Devesa, V.M. Arce, Growth hormone (GH) treatment may cooperate with locally-produced GH in increasing the proliferative response of hippocampal progenitors to kainate-induced injury, *Brain Inj.* 25 (2011) 503–510.
- [367] M. Heredia, A. Fuente, J. Criado, J. Yajeya, J. Devesa, A.S. Riobos, Early growth hormone (GH) treatment promotes relevant motor functional improvement after severe frontal cortex lesion in adult rats, *Behav. Brain Res.* 247 (2013) 48–58.
- [368] M.E. Diaz, J.G. Miquet, S.P. Rossi, P.E. Irene, A.I. Sotelo, M.B. Frungieri, et al., GH administration patterns differently regulate epidermal growth factor signaling, *J. Endocrinol.* 221 (2014) 309–323.
- [369] M. Sohmiya, K. Ishikawa, Y. Kato, Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure, *Eur. J. Endocrinol.* 138 (1998) 302–306.
- [370] R. Scharfmann, F. Atouf, A. Tazi, P. Czernichow, Growth hormone and prolactin regulate the expression of nerve growth factor receptors in INS-1 cells, *Endocrinology* 134 (1994) 2321–2328.
- [371] Devesa J, Devesa P, Reimunde P, Arce V. Growth Hormone and Kynestherapy for Brain Injury Recovery. *Brain Injury – Pathogenesis, Monitoring, Recovery and Management*. In: *Brain Injury-Pathogenesis, Monitoring, Recovery and Management*, 1st edition, Chapter:21, Publisher: In Tech. (Ed) A, Agrawal. 2012:417–54.
- [372] J. Devesa, C. Almenglo, P. Devesa, Multiple effects of growth hormone in the body: is it really the hormone for growth, *Clin. Med. Insights Endocrinol. Diabetes* 9 (2016) 47–71.
- [373] V.M. Arce, P. Devesa, J. Devesa, Role of growth hormone (GH) in the treatment on neural diseases: from neuroprotection to neural repair, *Neurosci. Res.* 76 (2013) 179–186.
- [374] J. Devesa, P. Reimunde, P. Devesa, M. Barbera, V. Arce, Growth hormone (GH) and brain trauma, *Horm. Behav.* 63 (2013) 331–344.
- [375] J. Devesa, G. Diaz-Getino, P. Rey, J. Garcia-Cancela, I. Loures, S. Nogueiras, et al., Brain recovery after a plane crash: treatment with growth hormone (GH) and neurorehabilitation: a case report, *Int. J. Mol. Sci.* 16 (2015) 30470–30482.
- [376] F. Sacca, M. Quarantelli, C. Rinaldi, T. Tucci, R. Piro, G. Perrotta, et al., A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results, *J. Neurol.* 259 (2012) 132–138.
- [377] J.Y. Chung, H.J. Kim, M. Kim, The protective effect of growth hormone on Cu/Zn superoxide dismutase-mutant motor neurons, *BMC Neurosci.* 16 (2015) 1.
- [378] M. Malek, S. Zahedi Asl, A. Sarkaki, Y. Farbood, A.H. Doulah, The effect of intra-hippocampal injection of growth hormone on spatial learning and memory in animal model of Alzheimer's disease, *Pak J. Biol. Sci.* 12 (2009) 1237–1245.
- [379] A.H. Doulah, A.H. Rohani, M. Khaksari Haddad, F. Motamedi, Y. Farbood, M. Badavi, et al., The effect of peripheral administration of growth hormone on AD-like cognitive deficiency in NBM-lesioned rats, *Neurosci. Lett.* 466 (2009) 47–51.
- [380] J.M. Saez, Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment, *Endocr. Metab. Immune Disord. Drug Targets* 12 (2012) 274–286.
- [381] P. Tollet-Egnell, A. Flores-Morales, N. Stahlberg, R.L. Malek, N. Lee, G. Norstedt, Gene expression profile of the aging process in rat liver: normalizing effects of growth hormone replacement, *Mol. Endocrinol.* 15 (2001) 308–318.
- [382] J.A. Tresguerres, R. Kireev, A.F. Tresguerres, C. Borrás, E. Vara, C. Ariznavarreta, Molecular mechanisms involved in the hormonal prevention of aging in the rat, *J. Steroid Biochem. Mol. Biol.* 108 (2008) 318–326.
- [383] D.P. Cardinali, E.S. Pagano, P.A. Scacchi Bernasconi, R. Reynoso, P. Scacchi, Melatonin and mitochondrial dysfunction in the central nervous system, *Horm. Behav.* 63 (2013) 322–330.
- [384] E. Miller, A. Morel, L. Saso, J. Saluk, Melatonin redox activity: its potential clinical applications in neurodegenerative disorders, *Curr. Top. Med. Chem.* 15 (2015) 163–169.
- [385] Z. Feng, C. Qin, Y. Chang, J.T. Zhang, Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease, *Free Radic. Biol. Med.* 40 (2006) 101–109.
- [386] J.M. Olcese, C. Cao, T. Mori, M.B. Mamcarz, A. Maxwell, M.J. Runfeldt, et al., Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease, *J. Pineal Res.* 47 (2009) 82–96.
- [387] M. Leone, D. D'Amico, F. Moschiano, F. Fraschini, G. Bussone, Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups, *Cephalalgia* 16 (1996) 494–496.
- [388] T. Pringsheim, E. Magnoux, C.F. Dobson, E. Hamel, M. Aube, Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study, *Headache* 42 (2002) 787–792.
- [389] E.A. Rudnitskaya, N.A. Muraleva, K.Y. Maksimova, E. Kiseleva, N.G. Kolosova, N.A. Stefanova, Melatonin attenuates memory impairment, amyloid- β accumulation, and neurodegeneration in a rat model of sporadic Alzheimer's disease, *J. Alzheimers Dis.* 47 (2015) 103–116.

- [390] L.C. Manchester, A. Coto-Montes, J.A. Boga, L.P. Andersen, Z. Zhou, A. Galano, et al., Melatonin: an ancient molecule that makes oxygen metabolically tolerable, *J. Pineal Res.* 59 (2015) 403–419.
- [391] J. Espino, I. Bejarano, S.D. Paredes, D. Gonzalez, C. Barriga, R.J. Reiter, et al., Melatonin counteracts alterations in oxidative metabolism and cell viability induced by intracellular calcium overload in human leucocytes: changes with age, *Basic Clin. Pharmacol. Toxicol.* 107 (2010) 590–597.
- [392] D. Acuna-Castroviejo, M. Martin, M. Macias, G. Escames, J. Leon, H. Khaldy, et al., Melatonin, mitochondria, and cellular bioenergetics, *J. Pineal Res.* 30 (2001) 65–74.
- [393] S.M. Hill, V.P. Belancio, R.T. Dauchy, S. Xiang, S. Brimer, L. Mao, et al., Melatonin: an inhibitor of breast cancer, *Endocr. Relat. Cancer* 22 (2015) R183–204.
- [394] A.M. Sanchez-Sanchez, I. Antolin, N. Puente-Moncada, S. Suarez, M. Gomez-Lobo, C. Rodriguez, et al., Melatonin cytotoxicity is associated to Warburg effect inhibition in ewing sarcoma cells, *PLoS One* 10 (2015) e0135420.
- [395] A. Garcia-Navarro, C. Gonzalez-Puga, G. Escames, L.C. Lopez, A. Lopez, M. Lopez-Cantarero, et al., Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture, *J. Pineal Res.* 43 (2007) 195–205.
- [396] A. Sanchez, A.C. Calpena, B. Clares, Evaluating the oxidative stress in inflammation: role of melatonin, *Int. J. Mol. Sci.* 16 (2015) 16981–17004.
- [397] V. Srinivasan, S.R. Pandi-Perumal, A. Brzezinski, K.P. Bhatnagar, D.P. Cardinali, Melatonin, immune function and cancer, *Recent Pat. Endocr. Metab. Immune Drug Discov.* 5 (2011) 109–123.
- [398] J. Vriend, R.J. Reiter, Breast cancer cells: modulation by melatonin and the ubiquitin-proteasome system –a review, *Mol. Cell. Endocrinol.* 417 (2015) 1–9.
- [399] F. Ortiz, D. Acuna-Castroviejo, C. Doerrier, J.C. Dayoub, L.C. Lopez, C. Venegas, et al., Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis, *J. Pineal Res.* 58 (2015) 34–49.
- [400] E. Anitua, C. Pascual, R. Perez-Gonzalez, D. Antequera, S. Padilla, G. Orive, et al., Intranasal delivery of plasma and platelet growth factors using PRGF-Endoret system enhances neurogenesis in a mouse model of Alzheimer's disease, *PLoS One* 8 (2013) e73118.
- [401] E. Anitua, C. Pascual, D. Antequera, M. Bolos, S. Padilla, G. Orive, et al., Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model, *Neurobiol. Aging* 35 (2014) 1582–1595.
- [402] E. Anitua, C. Pascual, R. Perez-Gonzalez, G. Orive, E. Carro, Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-kappaB-dependent inflammation process in a mouse model of Parkinson's disease, *J. Control. Release* 203 (2015) 170–180.
- [403] B.L. Conway-Campbell, J.W. Wooh, A.J. Brooks, D. Gordon, R.J. Brown, A.M. Lichanska, et al., Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 13331–13336.
- [404] R.W. Lea, T. Dawson, C.G. Martinez-Moreno, N. El-Abry, S. Harvey, Growth hormone and cancer: GH production and action in glioma, *Gen. Comp. Endocrinol.* 220 (2015) 119–123.
- [405] J.K. Perry, D.X. Liu, Z.S. Wu, T. Zhu, P.E. Lobie, Growth hormone and cancer: an update on progress, *Curr. Opin. Endocrinol. Diabetes Obes.* 20 (2013) 307–313.
- [406] R. Cao, M.A. Björndahl, P. Religa, S. Clasper, S. Garvin, D. Galter, et al., PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis, *Cancer Cell* 6 (2004) 333–345.
- [407] S. Harguindey, Apoptosis and antiapoptosis in cancer and neurodegenerative processes: a dialectic between opposites? New range of possibilities and potential dangers, *Oncología (Barcelona)*. 27 (2004) 27–37.